{"FinancialColumns":null,"FinancialHits":null,"TotalStockCount":0,"Securities":null,"OtcSecurities":null,"SortedSecurityCodes":null,"SearchId":"63b98164-32b2-4950-a793-6efe4f03b58e","TotalCompanyCardCount":56,"Total":81,"Took":878,"DbTook":0,"Hits":[{"Id":"52720752","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"tPJa3WyGbvFEkHfH2DD6WQ==","EncryptionKey":"dFBKYTNXeUdidkZFa0hmSDJERDZXUT09","Title":"香雪制药：2019年年度报告（更新后）","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-07-22T00:00:00","StockCode":"300147","StockTicker":"香雪制药","Url":"http://static.cninfo.com.cn/finalpage/2020-07-22/1208059659.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=cTHLjVz6FDCbXSwu01lDZXR2A0DgPBrZq+r1ZPe26Zv1NH4a2Batfw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300147/2020-07-22 2019年年度报告（更新后）.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;广州市香雪制药股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />广州市香雪制药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;20\u000020\u0000-\u00000\u000045\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 05 \u0000 月 \u0000<br />"},"Highlight":{"Content":["中药特点的新药开发新模式，推动<em>重大新药创制</em>和中药制剂等的中药新药研发。全面推动数字化转型，率"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"52341832","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"xAQ7H3cHQceYjGbS7vrr6A==","EncryptionKey":"eEFRN0gzY0hRY2VZakdiUzd2cnI2QT09","Title":"*ST辅仁：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-06-24T00:00:00","StockCode":"600781","StockTicker":"*ST辅仁","Url":"http://static.cninfo.com.cn/finalpage/2020-06-24/1207956929.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=7GmPwhvfmNrQz6wWNtoehaIMalIxkJGH0bicVnHRiaIby66ZnsL8Cg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600781/2020-06-24 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600781 \u0000 \u0000\t公司简称：\u0000 ST \u0000辅仁\u0000<br />辅仁药业集团制药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br /> \u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","战略性新兴产业作为国民经济支柱产业加快培育，“<em>重大新药创制</em>”科技及重大专项等科技计划"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"52261893","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"ceULcM/PlsAln0k2hACJJg==","EncryptionKey":"Y2VVTGNNL1Bsc0FsbjBrMmhBQ0pKZz09","Title":"ST康美：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-06-18T00:00:00","StockCode":"600518","StockTicker":"ST康美","Url":"http://static.cninfo.com.cn/finalpage/2020-06-18/1207936073.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=psKRYx0gYGrBjcQCTVSIKgsiZ/ePr1EBOhvd2Rh7fUzjDiB158GUVQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600518/2020-06-18 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600518 \u0000 \u0000 公司简称：\u0000 ST \u0000康美\u0000<br />&emsp;&emsp;康美药业股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000337\u0000<br />"},"Highlight":{"Content":["术突破与产业化应用”的子课题任务已分别启动执行，获批<em>重大新药创制</em>专项","个）团体标准获得发布，获批<em>重大新药创制</em>专项","@35@372@中医药国际合作专项:中国-加拿大中药新药筛选国际合作基地（广东）\t开展中药新药筛选平台的建设\t验收结题\t通过前期工作基础，获得国家中医药管理局的中医药国际合作专项，并通过验收。<hr style='margin:2px; border:none;' />基于中医典籍三化汤经典名方的研发\t国家科技重大专项-<em>重大新药创制</em>-课题名称：基于经方一致性评价技术的经典名方研究和开发\t试验阶段\t完成文献古籍调研，建立物质基准检测方法，完成 15 批物质基准制备及检测；收集不同产地药材各 15 批。<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"52247674","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"jBIqZqhS3emVrCeZSWMxSQ==","EncryptionKey":"akJJcVpxaFMzZW1WckNlWlNXTXhTUT09","Title":"亚宝药业：2019年年度报告（修正版）","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-06-17T00:00:00","StockCode":"600351","StockTicker":"亚宝药业","Url":"http://static.cninfo.com.cn/finalpage/2020-06-17/1207932283.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=pOaMPiEhxTi1vHzVUD/F+H9eaQSbTac5dXbLDpH9J/GxulMDMseW0g==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600351/2020-06-17 2019年年度报告（修正版）.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600351 \u0000 \u0000 公司简称：\u0000 亚宝药业\u0000<br />&emsp;&emsp;亚宝药业集团股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;(\u0000修订\u0000) \u0000<br />"},"Highlight":{"Content":["@154@2447@项目 \t期末余额 7,617,300.00 \t未偿还或结转的原因<hr style='margin:2px; border:none;' /><em>重大新药创制</em>科技重大专项 \t已经终止项目的政府补助款项，"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51993161","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"7AJkATaJ0rO14LmIDE0FMA==","EncryptionKey":"N0FKa0FUYUowck8xNExtSURFMEZNQT09","Title":"*ST中珠：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-05-30T00:00:00","StockCode":"600568","StockTicker":"*ST中珠","Url":"http://static.cninfo.com.cn/finalpage/2020-05-30/1207875407.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=6+MJ2jNpLrnqQLEUhB6vP9LK5bfhC35PV4+hLkiqWYB8ZMBwVEEKmQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600568/2020-05-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600568 \u0000 公司简称：中珠医疗\u0000<br />中珠医疗控股股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000242\u0000<br />"},"Highlight":{"Content":["@40@467@研发项目（含一致性评价项目）\t药（产）品基本信息\t研发（注册）所处阶段\t进展情况 \t累计研发投入\t已申报的厂家数量\t已批准的国产仿制厂家数量<hr style='margin:2px; border:none;' />益母草碱（SCM-198）\t可用于心脑血管保护 1.1 类新药，先后在国际、国内获得授权专利共 8 项。先后入选“十一五”计划“<em>重大新药创制</em>”的平台孵化药物、“十二五”计划“<em>重大新药创制</em>”的候选药物。具有降血脂，防治脑中风功效。\tI 期临床研究试验\t目前处于中国Ⅰ期临床研究阶段，已开展单次给药（入组 54 例）、食物影响（入组 16 例）、多次给药（入组 36 例）共3 个临床试验，目前均已完成全部临床数据收集及生物样本检测，正在开展统计分析报告和临床研究报告相关工作；向美国FDA 申报IND 资料正在进一步补充完善中。\t7,306.97 \t0 \t0<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51850521","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"kTNJL7ed4Szdz2Hv9/hKuA==","EncryptionKey":"a1ROSkw3ZWQ0U3pkejJIdjkvaEt1QT09","Title":"香雪制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-05-20T00:00:00","StockCode":"300147","StockTicker":"香雪制药","Url":"http://static.cninfo.com.cn/finalpage/2020-05-20/1207831755.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=ZTcyRY0QcRT58m2vBXNw/X7jIgzdopLV2ycAKvnjANUGVbvKNLvAEQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300147/2020-05-20 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;广州市香雪制药股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />广州市香雪制药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;20\u000020\u0000-\u00000\u000045\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 05 \u0000 月 \u0000<br />"},"Highlight":{"Content":["中药特点的新药开发新模式，推动<em>重大新药创制</em>和中药制剂等的中药新药研发。全面推动数字化转型，率"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51764326","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"JGSD9RjQuVCpb4xc3tUQlA==","EncryptionKey":"SkdTRDlSalF1VkNwYjR4YzN0VVFsQT09","Title":"九芝堂：2018年年度报告（更新后）","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-05-14T00:00:00","StockCode":"000989","StockTicker":"九芝堂","Url":"http://static.cninfo.com.cn/finalpage/2020-05-14/1207794337.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=Q38EykKlV4AJKUPDfnDw6ZsThl10+t9TuHVgq+2oPNGHGmQOdb+CcQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000989/2020-05-14 2018年年度报告（更新后）.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;九芝堂股份有限公司 \u0000 2018 \u0000年年度报告全文\u0000<br />证券代码：\u0000 000989 \u0000 证券简称：九芝堂 \u0000 \u0000\t公告编号：\u0000 20\u000020\u0000-\u00000\u000051\u0000<br />&emsp;&emsp;九芝堂股份有限公司\u0000<br />&emsp;&emsp;2018 \u0000 年年度报告\u0000<br />&emsp;&emsp;20\u000020 \u0000 年 \u0000 0\u00005 \u0000 月\u0000<br />"},"Highlight":{"Content":["项目已获评国家<em>重大新药创制</em>专项项目及海南省海口创新示范城市中孵化项目，预计共将陆续获得"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51471713","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"1hCHUQk/jsbb1+A3ZfjRnQ==","EncryptionKey":"MWhDSFVRay9qc2JiMStBM1pmalJuUT09","Title":"方盛制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"603998","StockTicker":"方盛制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207694875.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=x5jHAjSy5isQ3TA3Yli1kjCnG8doXqsj7CYpl5gc2XVQsfB0pLXR9w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/603998/2020-04-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：\u0000 603998 \u0000 \u0000 公司简称：\u0000 方盛制药\u0000<br />&emsp;&emsp;湖南方盛制药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;20\u000020 \u0000 年 \u0000 4 \u0000 月 \u0000 30 \u0000 日 \u0000<br />&emsp;&emsp;方盛制药·\u0000 2019 \u0000 年年度报告 \u0000<br />"},"Highlight":{"Content":["@197@2529@<table class='table-highlight' border='1'><tr class='tr-highlight'><td class='td-highlight'>负债项目 </td><td class='td-highlight'>期初余额 </td><td class='td-highlight'>本期新增补助金额</td><td class='td-highlight'>本期计入营业外收入金额</td><td class='td-highlight'>本期计入其他收益金额</td><td class='td-highlight'>其他变动 </td><td class='td-highlight'>期末余额</td><td class='td-highlight'>与资产相关/与收益相关</td></tr><tr class='tr-highlight'><td class='td-highlight'>“<em>重大新药创制</em>”科技重大专项经费-(益肝清毒颗粒临床试验研究) [注 2]</td><td class='td-highlight'>7,424,100.00 </td><td class='td-highlight'></td><td class='td-highlight'></td><td class='td-highlight'></td><td class='td-highlight'></td><td class='td-highlight'>7,424,100.00 </td><td class='td-highlight'>与收益相关</td></tr><tr class='tr-highlight'><td class='td-highlight'>“<em>重大新药创制</em>”科技重大专项经费-(迪安替康抗结直肠癌临床研究) [注 1]</td><td class='td-highlight'>6,731,000.00 </td><td class='td-highlight'></td><td class='td-highlight'></td><td class='td-highlight'></td><td class='td-highlight'></td><td class='td-highlight'>6,731,000.00 </td><td class='td-highlight'>与收益相关</td></tr>","年公司收到“<em>重大新药创制</em>”科技重大专项“十二五”第四","批子课题责任单位南京绿叶思科药业有限公司转拨付的“<em>重大新药创制</em>”科技重大专","@215@2822@种类 \t金额 \t列报项目 \t计入当期损益的金额<hr style='margin:2px; border:none;' />“<em>重大新药创制</em>”科技重大专项经费-(益肝清毒颗粒临床试验研究)\t7,424,100.00 \t递延收益<hr style='margin:2px; border:none;' />“<em>重大新药创制</em>”科技重大专项经费-(迪安替康抗结直肠癌临床研究)\t6,731,000.00 \t递延收益<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51478473","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"kSE/wm3t4zDOIPTmLLZ6/g==","EncryptionKey":"a1NFL3dtM3Q0ekRPSVBUbUxMWjYvZz09","Title":"人福医药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"600079","StockTicker":"人福医药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207688532.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=9ZR+DNRemdG8Zxp+EF87VskEy22n0d2msxYIA/EqgfBBPQZnneGGEA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600079/2020-04-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600079 \u0000 \u0000\t公司简称：\u0000 人福医药\u0000<br />&emsp;&emsp;人福医药集团股份公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;二\u0000○\u0000二〇\u0000年\u0000四\u0000月\u0000<br />"},"Highlight":{"Content":["@184@2589@高新区财政奖补资金 \t2,720,000.00<hr style='margin:2px; border:none;' /><em>重大新药创制</em>维吾尔药国际多中心临床研究与注册 \t1,397,100.001,244,000.00 \t820,115.54<hr style='margin:2px; border:none;' />","@185@2594@黄体酮新工艺专项资金 \t\t1,236,826.35 \t与资产相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>维吾尔药国际多中心临床研究与注册 \t1,397,100.00 \t\t与收益相关<hr style='margin:2px; border:none;' />","@194@2731@种类 \t金额 \t列报项目 \t计入当期损益的金额<hr style='margin:2px; border:none;' /><em>重大新药创制</em>维吾尔药国际多中心临床研究与注册 \t1,397,100.00 \t与收益相关 \t1,397,100.00<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51493372","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"a0Vf+VR2zyKGtikBURcd5Q==","EncryptionKey":"YTBWZitWUjJ6eUtHdGlrQlVSY2Q1UT09","Title":"吉药控股：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"300108","StockTicker":"吉药控股","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207687446.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=TwoboSBeH8+OArbe2H8awf3/EB9HRlkh+86zJT3xf83L0NuRdGU4zw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300108/2020-04-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;吉\u0000药\u0000控\u0000股\u0000集\u0000团\u0000股\u0000份\u0000有\u0000限\u0000公\u0000司 \u0000 2\u00000\u00001\u00009 \u0000年\u0000年\u0000度\u0000报\u0000告\u0000全\u0000文\u0000<br />吉\u0000药\u0000控\u0000股\u0000集\u0000团\u0000股\u0000份\u0000有\u0000限\u0000公\u0000司\u0000<br />2\u00000\u00001\u00009 \u0000 年\u0000年\u0000度\u0000报\u0000告\u0000<br />&emsp;&emsp;2\u00000\u00002\u00000\u0000-\u00000\u00005\u00000\u0000<br />2\u00000\u00002\u00000 \u0000 年 \u0000 0\u00004 \u0000 月\u0000<br />"},"Highlight":{"Content":["@160@2079@项目\t期初余额\t本期增加 \t本期减少 \t期末余额 \t形成原因<hr style='margin:2px; border:none;' />“<em>重大新药创制</em>”科技重大专项资金\t1,925,500.00\t\t \t1,925,500.00\t政府拨付<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51465922","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"UA4tBlNedNs6pMahK7K3pw==","EncryptionKey":"VUE0dEJsTmVkTnM2cE1haEs3SzNwdz09","Title":"奥赛康：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"002755","StockTicker":"奥赛康","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207682093.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=mjnC9Qv5Sne2/GHHtqna9sWBEFkOL/ZhzmooTdmxesCm8jIjfqnlyA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002755/2020-04-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;北京奥赛康药业股\u0000份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />北京奥赛康药业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>","@19@189@&emsp;&emsp;奥加明系国产首批上市的注射用雷贝拉唑钠，无进口对应产品，获得了国家<em>重大新药创制</em>科技重大专","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=mjnC9Qv5Sne2/GHHtqna9sWBEFkOL/ZhzmooTdmxesCm8jIjfqnlyA==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51465913","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"eXi7SUAnFEFZxnDKtxdPIQ==","EncryptionKey":"ZVhpN1NVQW5GRUZaeG5ES3R4ZFBJUT09","Title":"奥赛康：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"002755","StockTicker":"奥赛康","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207682092.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=K+1VN5wGDWIUU5oIuAL9sZu1Z369hi54XXfMyco4ptuoITpczBsx9A==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002755/2020-04-30 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002755\t证券简称：奥赛康（东方新星于2019年3月11日更名为奥赛康）\t公告编号：2020-009<br />&emsp;&emsp;北京奥赛康药业股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />董事、监事、高级管..."},"Highlight":{"Content":["@4@47@&emsp;&emsp;报告期内，公司承担 “<em>重大新药创制</em>”国家重大科技专项 “十三五课题”有7项。2019年9月17日，为落实国务院《关于改革完善仿制药供应保障及使用政策的意见》和《关于印发加快落实仿制药供应保障及使用政策工作方案的通知》，国家卫健委等部委发布《第一批鼓励仿制药品目录》（共33个药物），奥赛康在研的泊沙康唑、地拉罗司和福沙匹坦二甲葡胺等三个新品列入目录，其中泊沙康唑注射液已首家完成临床研究申报生产，该品种被列入“国家重大科技专项课题”，获得CDE的优先审评资格；地拉罗司分散片已首家完成临床生物等效性试验并申报生产，该品种被列入了“国家重大科技专项课题”。","@7@79@&emsp;&emsp;2019年奥赛康药业创新能力再次获得国家主管部委的认定，分别由国家发展改革委、科技部、财政部、海关总署、税务总局等部委共同认定为国家企业技术中心；由国家工信部认定为国家技术创新示范企业；新增获得3个国家“十三五”期间“<em>重大新药创制</em>”科技重大专项课题立项。同时江苏省手性药物重点实验室以优秀等级通过省科技厅验收，拥有了化学药的高效、高选择性不对称催化反应的不对称氢化、氧化以及偶联反应、糖苷键构建、生物酶催化等手性定向合成技术及配体等关键技术，并应用于奥赛康药业核心领域的手性药物的研发；在政府主管部门对江苏省抗消化道溃疡药物工程技术研究中心、江苏省靶向抗肿瘤药物工程中心、江苏省企业技术中心、江苏省手性药物重点实验室四合一综合绩效考评中，获得优秀等级；在南京市创新名城建设中被市委市政府评定为南京市最具创新力企业。","@8@88@&emsp;&emsp;奥加明系国产首批上市的注射用雷贝拉唑钠，无进口对应产品，获得了国家<em>重大新药创制</em>科技重大专项立项、中国专利金奖。","@8@92@&emsp;&emsp;手性质子泵抑制剂领域构建关键共性技术的核心聚集体系。公司承担国家“十三五”期间“<em>重大新药创制</em>”科技重大专项课题“手性质子泵抑制剂系列产品关键技术研发及产业化”，课题涉及8个手性PPI品种的研发，包括右雷贝拉唑钠及注射剂、左泮托拉唑钠及注射剂、右兰索拉唑及注射剂、右兰索拉唑双相缓释胶囊、儿童用艾司奥美拉唑镁干混悬剂，上述产品将进一步夯实奥赛康药业在消化系统用药领域的市场竞争力，增强持续盈利能力。","@9@96@&emsp;&emsp;抗肿瘤创新药获得重要进展。创新药ASK120067项目，2019年获得国家“十三五”“<em>重大新药创制</em>”科技重大专项课题立项。肺癌是中国发病率第一的恶性肿瘤，ASK120067是靶向作用于T790M的三代EGFR抑制剂，用于治疗非小细胞肺癌；国际上批准的T790M抑制剂，2019年中国销售额达31.9亿元，；国内同治疗机理的品种只有进口产品，一旦研发成功可打破国外垄断，大大节约国家医保支出。2019年5月","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=K+1VN5wGDWIUU5oIuAL9sZu1Z369hi54XXfMyco4ptuoITpczBsx9A==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51461695","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"KqTUzzwjybNJ0tK/aCorrw==","EncryptionKey":"S3FUVXp6d2p5Yk5KMHRLL2FDb3Jydz09","Title":"九芝堂：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"000989","StockTicker":"九芝堂","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207679259.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=tCtHywivHT2mUNITbGBxvnYgK9NwU+WMKis/o6lzLAqgSy15arMa7w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000989/2020-04-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;九芝堂股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />九芝堂股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020\u0000-\u0000022\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["重大专项<em>重大新药创制</em>天然产物来源创新药物新品种研发及其关键创新技术体系"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51468699","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"WPzu+wR7IOQXJvUP1SB4MA==","EncryptionKey":"V1B6dSt3UjdJT1FYSnZVUDFTQjRNQT09","Title":"中关村：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"000931","StockTicker":"中关村","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207684909.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=RUq0qMh61zyO6qoWcpTveGiAyyRxRfZiMlPmrs96W9eQnxSk7g7yuA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000931/2020-04-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;北京中关村科技发展\u0000(\u0000控股\u0000)\u0000股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />北京中关村科技发展（控股）股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020\u0000-\u0000039\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["@197@2482@创新能力建设专项资金\t\t\t（按国家级政策规定依法取得）<hr style='margin:2px; border:none;' />关于双黄连注射液过敏标志物及预警体系的研究补贴款\t\"<em>重大新药创制</em>\"科技重大专项实施管理办公室\t补助\t因研究开发、技术更新及改造等获得的补助\t是 \t否 \t\t728,600.00 \t与收益相关<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51469534","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Zx0iuRn52pbMw8M+WVelyQ==","EncryptionKey":"WngwaXVSbjUycGJNdzhNK1dWZWx5UT09","Title":"海南海药：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-30T00:00:00","StockCode":"000566","StockTicker":"海南海药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-30/1207685460.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=rzXlcaP+SewNiZPtDvdg9uimwRO2uN0mcdV0U8F9JJKxt4HN6pzvWA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000566/2020-04-30 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：000566 \t证券简称：海南海药\t公告编号：2020-041<br />&emsp;&emsp;海南海药股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />董事、监事、高级管理人员异议声明<br />"},"Highlight":{"Content":["@8@82@&emsp;&emsp;1.通过与中国抗体的投资合作，由梁瑞安博士为首的专家团队研发并获得全球PCT专利原创新药SM03，主要用于治疗类风湿关节炎、肿瘤及免疫系统疾病，且为全球原创新药。其中，主治类风湿关节炎的生物制品，已进入Ⅲ期临床试验，患者招募即将完成。其他淋巴瘤、红斑狼疮两适应症计划进入Ⅱ期临床。中国抗体的SM03研究项目已获得国家科技重大专项“<em>重大新药创制</em>”立项。抗肿瘤及治疗免疫系统疾病的新药SM09、SM06、TNF2等正在进行临床前研究。中国抗体已于2019年11月在香港联交所上市，IPO募集金额约12.7亿港币。","@8@83@&emsp;&emsp;2.与中南大学合作研发的肝纤维化治疗药——国家1.1类新药氟非尼酮，已完成单次给药剂量耐受性试验和食物对药代动力学影响试验，开展多次给药的安全性和药代动力学研究。该产品拥有自主知识产权，化合物已获得PCT专利，并得到国家“<em>重大新药创制</em>”科技重大专项立项支持。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-92277","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"lSy0+c3DSC/dVg54kBOmJw==","EncryptionKey":"bFN5MCtjM0RTQy9kVmc1NGtCT21Kdz09","Title":"百奥泰：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"688177","StockTicker":"百奥泰","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207661107.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=VemJDSghLQXTSvpe+ykH5sww/0TlC8ztupiQl3t4MUB9wssgENofYA==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688177/2020-04-29 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688177\t公司简称：百奥泰<br />百奥泰生物制药股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一 重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 重大风险提示<br />"},"Highlight":{"Content":["@12@119@&emsp;&emsp;“百奥泰人源抗体创新药物孵化基地”课题获得“十二五”国家<em>重大新药创制</em>科技重大专项立项支持；公司“肿瘤治疗性抗体药物研发及全球临床Ⅲ期试验”课题于2018年获得<em>重大新药创制</em>科技重大专项立项支持；百奥泰生物科技研究院（承担单位为百奥泰）2016年度被广东省科学技术厅认定为广东省新型研发机构，广东省抗体偶联药物工程技术研究中心（依托单位为百奥泰）2016年度被广东省科学技术厅认定为广东省工程技术研究中心；2018年被广东省发展和改革委员会认定为广东省抗体药物偶联生物医药工程实验室（广东省工程实验室）。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-92362","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"MrxKADaXM3eRpRwmrTl6JQ==","EncryptionKey":"TXJ4S0FEYVhNM2VScFJ3bXJUbDZKUT09","Title":"百奥泰：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"688177","StockTicker":"百奥泰","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207669283.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=fyRjBPmTreWb34+1/BAhJH9QJ5Zt7cpNl3cB4KXzlvCFtoEMFJUKIA==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688177/2020-04-29 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688177\t公司简称：百奥泰<br />百奥泰生物制药股份有限公司<br />&emsp;&emsp;2019 年年度报告<br />&emsp;&emsp;1/ 236<br />&emsp;&emsp;重要提示<br />"},"Highlight":{"Content":["@22@218@&emsp;&emsp;“百奥泰人源抗体创新药物孵化基地”课题获得“十二五”国家<em>重大新药创制</em>科技重大专项立项支持；公司“肿瘤治疗性抗体药物研发及全球临床Ⅲ期试验”课题于2018年获得<em>重大新药创制</em>科技重大专项立项支持；百奥泰生物科技研究院（承担单位为百奥泰）2016年度被广东省科学技术厅认定为广东省新型研发机构，广东省抗体偶联药物工程技术研究中心（依托单位为百奥泰）2016年度被广东省科学技术厅认定为广东省工程技术研究中心；2018年被广东省发展和改革委员会认定为广东省抗体药物偶联生物医药工程实验室（广东省工程实验室）。","@24@245@&emsp;&emsp;研发的具有完全自主知识产权的药物-连接子美登素衍生物“Batansine”具有很好的稳定性。该技术采用不可切割型的连接子，在血液循环中小分子毒素不会脱落，因此稳定性较好，体内安全性较高。此外，公司的研发团队创造性开发出一种新颖、高效、成本低的催化偶联方法，极大降低了规模化生产成本。目前，Batansine 技术已获得多项国内外专利授权。基于此平台开发的BAT8001获得广东省以及广州市科技重大专项支持，并被国家卫计委“<em>重大新药创制</em>”专项专家组推荐为优先审评药物品种；BAT8003采用新一代定点偶联技术，将小分子毒性药物定点定量偶联在抗体上，从而改善了 ADC 产物的均一性，BAT8003 已向中国、美国和 WIPO（世界知识产权组织）等提交多项专利申请。","@31@300@&emsp;&emsp;BAT8001 为国内药企首家进入中国Ⅲ期临床试验研究的曲妥珠单抗偶联药物，其相关技术已获得多项中国和美国专利授权。作为公司自主研发的一类新药，BAT8001 获得广东省以及广州市科技重大专项支持，并被国家卫计委“<em>重大新药创制</em>”专项专家组推荐为优先审评药物品种。","@32@315@&emsp;&emsp;公司董事、副总经理 YUJIN-CHEN（俞金泉）博士为肿瘤生物学领域资深专家，拥有超过 20 年的癌症基础研究及药物研发经验，于 2013 年入选“广东省珠江人才计划”创新创业团队成员。管理团队的其他主要成员也具备较强的业务背景。公司监事会主席兼高级总监吴晓云被评为“广州市青年后备人才”、广州开发区精英人才，拥有超过 10 年的医药研究经验；公司监事兼研发部总监汤伟佳被评为“广州市产业急需紧缺人才”，为多个在研创新ADC的主要发明人。监事兼生产运营高级总监包财被评为“广州市开发区骨干人才和紧缺人才”，参与若干国家<em>重大新药创制</em>专项、广州市科技创新项目。","@39@379@&emsp;&emsp;“百奥泰人源抗体创新药物孵化基地”课题于2013年获得“十二五”国家<em>重大新药创制</em>科技重大专项立项支持；公司“肿瘤治疗性抗体药物研发及全球临床Ⅲ期试验”课题于2018年获得<em>重大新药创制</em>科技重大专项立项支持；百奥泰生物科技研究院（承担单位为百奥泰有限）2016年度被广东省科学技术厅认定为广东省新型研发机构，广东省抗体偶联药物工程技术研究中心（依托单位为百奥泰有限）2016年度被广东省科学技术厅认定为广东省工程技术研究中心；2018年7月被广东省发展和改革委员会认定为广东省抗体药物偶联生物医药工程实验室（广东省工程实验室）。","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=fyRjBPmTreWb34+1/BAhJH9QJ5Zt7cpNl3cB4KXzlvCFtoEMFJUKIA==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51448757","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"shTMoyV45Fbd5zVJu8HYeg==","EncryptionKey":"c2hUTW95VjQ1RmJkNXpWSnU4SFllZz09","Title":"翰宇药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"300199","StockTicker":"翰宇药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207667462.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=an5O+AkRPCHX/HJEp/YwoaURHe/FYRBa3AqcLayWFQmY/LqniRBQPg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300199/2020-04-29 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;深圳翰宇药业股份\u0000有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />深圳翰宇药业股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["@188@2114@负债项目 \t期初余额 \t本期新增补助金额\t本期计入其他收益金额 \t其他变动 \t期末余额 \t与资产相关/与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>-长效催产素受体激动剂卡贝缩宫素的研究与开发\t234,416.32 \t- \t58,604.08 \t- \t175,812.24 \t与资产相关<hr style='margin:2px; border:none;' />","@195@2162@项目 \t本期发生额 \t上期发生额\t与资产相关/与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>-长效催产素受体激动剂卡贝缩宫素的研究与开发项目 \t58,604.08 \t1,265,583.68 \t与资产相关<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51442740","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"VIq7zohlBOaaVDVWT8yqdQ==","EncryptionKey":"VklxN3pvaGxCT2FhVkRWV1Q4eXFkUT09","Title":"龙津药业：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"002750","StockTicker":"龙津药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207663130.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=dZoaLmPSxrkQRKNj39urT2fRU5RiKl5lz9bQGEkpA1x/icaKCXa1hA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002750/2020-04-29 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002750 \t证券简称：龙津药业\t公告编号：2020-016<br />&emsp;&emsp;昆明龙津药业股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />"},"Highlight":{"Content":["@3@54@公司已拥有近30项国内、外发明专利，多次承担国家级和云南省级<em>重大新药创制</em>、中药标准化和产业振兴专项项目并成功结题。龙津 ® 注射用灯盏花素作为公司在销主要产品，连续两次被列为国家二级中药保护品种。由公司起草的注射用灯盏花素质量标准被载入《中国药典》，为《中国药典》中收载的5个中药注射剂之一，是唯一纯度达到98%的单体成分中药制剂，其纯度完全能够按照化学药标准来衡量，是国内一直探讨的中西医结合方法及理论的典型案例。国家食药监局已核发注射用灯盏花素生产批件6个，本公司持有其中3个，其中1个为独家规格。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51442758","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"31huwlzIYbsORkFwAdZk5Q==","EncryptionKey":"MzFodXdseklZYnNPUmtGd0FkWms1UT09","Title":"龙津药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"002750","StockTicker":"龙津药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207663131.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=kGeNKtgoloYTMqTomcokwBiM7UoRmqFxsUPGMtwSgXGq5lJ5MQIt5w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002750/2020-04-29 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;昆明龙津药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />昆明龙津药业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020\u0000-\u0000017\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["项国内、外发明专利，多次承担国家级和云南省级<em>重大新药创制</em>、中药标准化和产业振兴专项项目并成功"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51418160","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"TV+LeoUFnuTaTHUpQjov8A==","EncryptionKey":"VFYrTGVvVUZudVRhVEhVcFFqb3Y4QT09","Title":"奇正藏药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"002287","StockTicker":"奇正藏药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207654643.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=EGBw9MRXeC0VuNFQp3WbL+yzICWfce/uA0EEDKSyVLIa0n4x5rwSGg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002287/2020-04-29 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"西藏奇正藏药股份有限公司\u0000<br />Tibet Cheezheng Tibetan Medicine Co.,Ltd\u0000<br />2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;证券代码：\u0000 002287\u0000证券简称：奇正藏药\u0000<br />&emsp;&emsp;中国 \u0000 \u0000 西藏\u00002020\u0000年\u000004\u0000月\u0000<br />"},"Highlight":{"Content":["@209@2415@铁棒锤、白脉软膏新工艺生产藏药外用透皮制剂高技术\t581,711.04 \t1,112,069.20<hr style='margin:2px; border:none;' />十二五<em>重大新药创制</em>项目 \t\t3,729,000.00"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51423298","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Bgz9fTYYOtw7zMK6qzEUAA==","EncryptionKey":"Qmd6OWZUWVlPdHc3ek1LNnF6RVVBQT09","Title":"沃华医药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"002107","StockTicker":"沃华医药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207659981.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=QObahGgJdm4VArdAYPEZhwuM98BPpzf2sGO7V+EHZEX7TrC1blQ1vA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002107/2020-04-29 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;山东沃华医药科技股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />山东沃华医药科技股份有限公司\u0000<br />Shandong Wohua Pharmaceutical Co., \u0000 Ltd\u0000<br />&emsp;&emsp;二\u0000〇\u0000一九\u0000年年度报告\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["计划、<em>重大新药创制</em>专项、山东省科技重大专项等项目支持，获得国家科学技术进步二等奖、","国家中药标准化项目、国家<em>重大新药创制</em>等项目","国家<em>重大新药创制</em>","@28@273@序号 \t项目名称 \t项目类型 \t合作单位<hr style='margin:2px; border:none;' />6 \t中药智能制造关键技术研究与应用 \t国家<em>重大新药创制</em>专项 \t山东大学<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51423290","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"OBt9Adv5qiEFPsDpOhxnfw==","EncryptionKey":"T0J0OUFkdjVxaUVGUHNEcE9oeG5mdz09","Title":"沃华医药：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-29T00:00:00","StockCode":"002107","StockTicker":"沃华医药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-29/1207659977.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=M9qqp5RnaUM2s6FORP5IExTKJBwnYiJfLFHL9IyUchnXMN68H/q7GQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002107/2020-04-29 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002107\t证券简称：沃华医药\t公告编号：2020-025<br />&emsp;&emsp;山东沃华医药科技股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />&emsp;&emsp;本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />非标准审计意见提示<br />"},"Highlight":{"Content":["@4@37@&emsp;&emsp;沃华 ® 心可舒片是沃华医药联合潍坊人民医院、潍坊医学院等医疗、科研机构，收集治疗冠心病的有效验方，经多方论证，通过药学、药理学和临床等研究并获批生产的独家中药品种，国家医保乙类品种、载录《国家基本药物目录（2018年版）》、国家中药保护品种。沃华 ® 心可舒片治疗冠心病、心绞痛、高血压、心律失常、高脂血症等常见心血管疾病。是唯一具有“双心效应”的独家专利药，在治疗心血管疾病的同时又可有效缓解患者心慌焦虑、心烦易怒等不良情绪。沃华 ® 心可舒片符合心血管疾病二级防治ABCDE原则，纯植物组方，长期服用安全性好。公司投入大量资金开展沃华 ® 心可舒片的基础及临床研究，先后获得863计划、<em>重大新药创制</em>专项、山东省科技重大专项等项目支持，获得国家科学技术进步二等奖、中国制药品牌榜新锐品牌、百姓放心药等众多荣誉。沃华 ® 心可舒片获得国家发明专利5项，先后被《经皮冠状动脉介入治疗（PCI）术后胸痛中医诊疗专家共识》、《经皮冠状动脉介入治疗（PCI）手术前后抑郁和（或）焦虑中医诊疗专家共识》、《心理应激导致稳定性冠心病患者心肌缺血的诊断和治疗专家共识》、《动脉粥样硬化中西医结合诊疗专家共识》、《动脉粥样硬化中西医结合诊疗专家共识》、《血脂异常中西医结合诊疗专家共识》等12项路径、指南、共识收录，用于治疗心血管疾病，改善相关症状。以沃华 ®心可舒片为研究对象的学术论文已发表400余篇，其中SCI论文发表10篇。基础研究表明，沃华 ® 心可舒片可以保护血管内皮，降低炎症因子水平，抗动脉粥样硬化，抗心肌缺血。临床研究显示，沃华 ® 心可舒片可有效治疗冠心病合并不良情绪患者，在治疗冠心病等的同时，调节患者不良情绪。介入术后患者、高血压合并双心疾病患者、心律失常合并双心疾病患者加服沃华 ® 心可舒片后，在改善心血管疾病临床症状的同时，不良情绪均得到改善，患者临床反馈效果明显。还有研究发现，沃华 ® 心可舒片可以降低血小板聚集率，调节心律，改善动脉僵硬度。","@5@42@&emsp;&emsp;荷丹片/胶囊是济顺制药独家原研产品，方源名老中医、李先念主席的保健医师——杨济生老先生的调脂、减肥、保肝、延寿之方，为李先念主席写的轻身延年方，国家医保乙类品种、载录《国家基本药物目录（2018年版）》。荷丹片/胶囊由荷叶、山楂、丹参、番泻叶、补骨脂（盐制）五味药材科学配伍而成，是一款可以有效改善糖脂代谢异常的纯植物调脂药，具有活血化瘀、化痰降浊的功效，同时调脂护肝，减重通便，适合甘油三酯增高及混合性血脂异常患者。凭借其独特的疗效及临床价值，荷丹片/胶囊先后获得国家中药标准化项目、国家<em>重大新药创制</em>等项目支持，获得4项国家发明专利，先后进入中华中医药学会、国家中医药管理局、国家心血管病中心等机构发布的《中成药临床应用指南-心病分册》、《国家中医药管理局临床路径》、《血脂异常中西医结合诊疗专家共识》等7项指南、路径和共识。以荷丹片/胶囊为研究对象的学术论文已发表100余篇。基础研究表明，高剂量荷丹片/胶囊通过调节血脂、改善肥胖状态及胰岛素抵抗，有抗动脉粥样硬化的作用，可抑制动脉粥样硬化的发生、发展。临床研究显示，荷丹片/胶囊治疗8周可以改善脂蛋白胆固醇水平。荷丹片/胶囊联合阿托伐他汀可显著改善中青年血脂异常患者血脂水平，增强调脂效果，且不良反应少。单独服用荷丹片/胶囊与他汀类疗效相似，荷丹片/胶囊联用他汀类药物能够更好的降低原发混合型高脂血症患者总胆固醇水平。","@17@155@发出具有“双心效应”，符合心血管疾病二级防治ABCDE原则，适合患者长期服用的纯植物中成药，证明了该理论的创新性与科学性。公司开展的“国家<em>重大新药创制</em>专项——中药口服制剂先进制造关键技术与示范研究”、“2019年山东半岛国家自主创新示范区发展建设”等5个项目已获得有关主管机构立项，按照项目计划逐步顺利实施。其中“中药口服制剂先进制造关键技术与示范研究”项目与山东大学联合开展，获得2019年度国家重点研发计划项目立项。","@17@157@目名称\t目类型\t作单位<hr style='margin:2px; border:none;' />6\t中药智能制造关键技术研究与应用\t国家<em>重大新药创制</em>专项\t山东大学<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-91895","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Jz/X7Rnpw8ICn60oZhrcHg==","EncryptionKey":"SnovWDdSbnB3OElDbjYwb1pocmNIZz09","Title":"泽璟制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"688266","StockTicker":"泽璟制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207650784.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=c8SjBkfe/ubw1DYFX8TSl1EXWKiPjuTogM9GCe9LPZAbZXzmwAKdyA==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688266/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688266\t公司简称：泽璟制药<br />苏州泽璟生物制药股份有限公司<br />&emsp;&emsp;2019 年年度报告<br />&emsp;&emsp;重要提示<br />一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，<br />"},"Highlight":{"Content":["@14@135@&emsp;&emsp;多纳非尼是小分子靶向1类新药，具有多重抗肿瘤机制，对多种晚期恶性肿瘤均具有显著的治疗效果。多纳非尼共获得 4 项“十二五”和“十三五”国家<em>重大新药创制</em>科技重大专项立项支持，是目前国内唯一完成III期临床试验的一线治疗晚期肝细胞癌的国产分子靶向新药，并获得新药特殊审批资格，于 2020 年一季度提交 NDA，有望成为治疗晚期肝细胞癌同类更佳的药物。多纳非尼具有广谱抗肿瘤效果和良好的安全性，具有显著的调节肿瘤免疫微环境的作用，使得其具有与肿瘤免疫治疗药物（I/O）联合治疗的潜力，进一步提升肿瘤治疗的疗效。目前公司已经与多家拥有抗PD-1/PD-L1抗体产品的制药企业形成战略合作，正在启动多项联合治疗临床研究，以期获得更大的市场空间。","@15@138@&emsp;&emsp;杰克替尼是JAK抑制剂类靶向小分子1类新药，是目前中国处于治疗骨髓纤维化II期临床试验阶段的唯一在研新药。杰克替尼已获得“国家<em>重大新药创制</em>”科技重大专项支持。同时，公司正启动盐酸杰克替尼片治疗重症斑秃、强直性脊柱炎等自身免疫相关疾病的临床试验，这些适应症的开发使其拥有独特的竞争力。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-91898","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Jz/X7Rnpw8LT5jWz9V18xw==","EncryptionKey":"SnovWDdSbnB3OExUNWpXejlWMTh4dz09","Title":"泽璟制药：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"688266","StockTicker":"泽璟制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207650781.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=c8SjBkfe/uYosPNJcUn5mUtd0fof+3FwS9P/G9iQBBVWZQXynv1gPw==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688266/2020-04-28 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688266\t公司简称：泽璟制药<br />苏州泽璟生物制药股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一 重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 重大风险提示<br />"},"Highlight":{"Content":["@7@66@&emsp;&emsp;多纳非尼是小分子靶向1类新药，具有多重抗肿瘤机制，对多种晚期恶性肿瘤均具有显著的治疗效果。多纳非尼共获得4项“十二五”和“十三五”国家<em>重大新药创制</em>科技重大专项立项支持，是目前国内唯一完成III期临床试验的一线治疗晚期肝细胞癌的国产分子靶向新药，并获得新药特殊审批资格，于2020年一季度提交NDA，有望成为治疗晚期肝细胞癌同类更佳的药物。多纳非尼具有广谱抗肿瘤效果和良好的安全性，具有显著的调节肿瘤免疫微环境的作用，使得其具有与肿瘤免疫治疗药物（I/O）联合治疗的潜力，进一步提升肿瘤治疗的疗效。目前公司已经与多家拥有抗PD-1/PD-L1抗体产品的制药企业形成战略合作，正在启动多项联合治疗临床研究，以期获得更大的市场空间。","@7@68@&emsp;&emsp;杰克替尼是JAK抑制剂类靶向小分子1类新药，是目前中国处于治疗骨髓纤维化II期临床试验阶段的唯一在研新药。杰克替尼已获得“国家<em>重大新药创制</em>”科技重大专项支持。同时，公司正启动盐酸杰克替尼片治疗重症斑秃、强直性脊柱炎等自身免疫相关疾病的临床试验，这些适应症的开发使其拥有独特的竞争力。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51392856","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"dYFy10PulZBdwQCUsxWnSw==","EncryptionKey":"ZFlGeTEwUHVsWkJkd1FDVXN4V25Tdz09","Title":"步长制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"603858","StockTicker":"步长制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207650451.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=7pxDboXFS7teg6FbBjQzMNtMzqd9yGyCYRprYtgKTqOpOBN9YkV/pQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/603858/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"山东步长制药股份有限公司 \u0000 201\u00009 \u0000年年度报告 \u0000 \u0000<br />公司代码：\u0000 603858 \u0000 \u0000 公司简称：\u0000 步长制药\u0000<br />&emsp;&emsp;山东步长制药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000215\u0000<br />"},"Highlight":{"Content":["根据国家卫生计生委医药卫生科技发展研究中心《关于“<em>重大新药创制</em>”科技重大专","<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>","司共同申报“<em>重大新药创制</em>”科技重大专项“中药矫味技术及其在小儿健胃咀嚼片中的应用”，","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=7pxDboXFS7teg6FbBjQzMNtMzqd9yGyCYRprYtgKTqOpOBN9YkV/pQ==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51397204","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"V9ioMkrN3EGf7QPkKJUCLA==","EncryptionKey":"Vjlpb01rck4zRUdmN1FQa0tKVUNMQT09","Title":"太极集团：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"600129","StockTicker":"太极集团","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207646549.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=fu3mQ52yQVYYGKAc1xW9KAFuIRyJ7CzfNxYz6xqpYq5vK5JrOGa/0Q==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600129/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600129 \u0000 \u0000 公司简称：\u0000 太极集团\u0000<br />重庆太极实业（集团）股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;二 \u0000 0 \u0000 二 \u0000 0 \u0000 年四月\u0000<br />"},"Highlight":{"Content":["@23@323@金额 \t费用化金额\t资本化金额\t占营业收入比例（%）\t占营业成本比例（%）\t上年同期变动比例（%）\t说明<hr style='margin:2px; border:none;' />创新中药丹七通脉片\t1,052.33 \t1,052.33 \t\t0.09 \t0.16 \t511.78 \t“十三五”<em>重大新药创制</em>专项<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51414559","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"8rTuZmYKGjoBUOvguQuIBg==","EncryptionKey":"OHJUdVptWUtHam9CVU92Z3VRdUlCZz09","Title":"康泰生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"300601","StockTicker":"康泰生物","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207645110.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=NlRp75eAfNe6U3abosJAgyDuq9vzioD4Zbx/AkvJui2tJ+ZM8r1Q9g==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300601/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;深圳康泰生物制品股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />深圳康泰生物制品股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1 \u0000<br />"},"Highlight":{"Content":["@162@1796@产生其他收益的来源 \t本期发生额 \t上期发生额<hr style='margin:2px; border:none;' />国家卫计委“<em>重大新药创制</em>”5 价流脑多糖蛋白结合疫苗”项 目\t5,127,200.00<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51388867","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"uvxdu1cNDK/eeq3nnb9cYQ==","EncryptionKey":"dXZ4ZHUxY05ESy9lZXEzbm5iOWNZUT09","Title":"罗欣药业：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002793","StockTicker":"罗欣药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207640878.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=Xlgu0SH3jgpuiYtDzjFosbMwL0Qkl9I1GMlbyGyzhJfHJK76KO6fFQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002793/2020-04-28 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002793 \t证券简称：东音股份<br />&emsp;&emsp;浙江东音泵业股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />2019年度公司实施重大资产置换及发行股份购买资产暨关联交易事项，以重大资产置换及发行股份..."},"Highlight":{"Content":["@3@40@&emsp;&emsp;根据NMPA数据显示，罗欣药业系当前国内唯一获批的头孢西酮钠原料药生产商。罗欣药业盐酸氨溴索原料药最大产能可达120吨/年、居于行业前列。目前，罗欣药业拥有药品注册批件300余项，同时积极发掘非洲、南美洲及部分“一带一路”国家等新兴市场的机会，有39项药品注册批件在菲律宾、埃塞俄比亚、玻利维亚、乌克兰等国家申请中。罗欣药业11个产品被列入国家“<em>重大新药创制</em>”科技重大专项、4个产品被列入“国家重点新产品计划”、12个产品被列入“国家火炬计划”、139个项目被列入“山东省火炬计划、山东省科技发展计划、山东省技术创新项目”。罗欣药业多项产品获得“科学技术进步奖”，其中“化学药物晶型关键技术体系的建立与应用”技术荣获国家科技进步奖二等奖。新型钾离子竞争性酸阻滞剂（P-CAB）药物LXI-15028的临床研究”被列入“<em>重大新药创制</em>”国家科技重大专项计划。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51388877","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"jiPRF0c9YpsE2PZ/dOFQqA==","EncryptionKey":"amlQUkYwYzlZcHNFMlBaL2RPRlFxQT09","Title":"罗欣药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002793","StockTicker":"罗欣药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207640879.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=IUIqWtKKFbbS6URo7wi383Srh3EtN3zu/r2tAcRZqCOkh5X89hki4A==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002793/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;浙江东音泵业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />浙江东音泵业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","的临床研究”被列入“<em>重大新药创制</em>”国家科技重大专项计划。","<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51386171","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"mWckdqW9dNm7kFMVL5JkXw==","EncryptionKey":"bVdja2RxVzlkTm03a0ZNVkw1SmtYdz09","Title":"以岭药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002603","StockTicker":"以岭药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207638477.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=BsP5UFYbQaeLuYQZDY4NDuMsJTW8C4Ezi6IyYuyOLyhNfnOS/7AprQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002603/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;石家庄以岭药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />石家庄以岭药业股份有限公司\u0000<br />SHIJIAZHUANG YILING PHARMACEUTICAL CO.,LTD\u0000<br />&emsp;&emsp;（河北省石家庄市高新技术产业开发区天山大街 \u0000 238 \u0000 号）\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>等三十余项国家、省部级科","@189@2171@专利中药（胶囊剂、颗粒剂）生产基地建设项目\t19,595,692.04 \t\t\t4,118,611.98 \t\t\t15,477,080.06 \t与资产相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>中药芪苈强心胶囊对慢性心力衰竭患者长期预后及安全性上市后评价的随机双盲、安慰剂对照、多中心临床试验项目\t3,925,000.00 \t\t\t\t\t\t3,925,000.00 \t与收益相关<hr style='margin:2px; border:none;' />","@192@2180@2018 年石家庄高新区发展专项资金-苯胺洛芬一期临床研究项目\t900,000.00 \t\t\t\t\t\t900,000.00 \t与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>连花清瘟生产技术改造研究项目\t759,100.00 \t\t\t\t\t\t759,100.00 \t与收益相关<hr style='margin:2px; border:none;' />","@193@2183@芪黄明目胶囊治疗糖尿病视网膜病变的临床研究项目\t273,800.00 \t\t\t\t\t\t273,800.00 \t与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>周络通胶囊治疗糖尿病周围神经病变的新药临床研究项目\t242,800.00 \t\t\t\t\t\t242,800.00 \t与收益相关<hr style='margin:2px; border:none;' />","@194@2186@重大专项参松养心胶囊生产工艺优化关键技术研究项目\t30,000.12 \t\t\t9,999.96 \t\t\t20,000.16 \t与资产相关<hr style='margin:2px; border:none;' />国家科技重大专项“<em>重大新药创制</em>”项目\t50,000.00 \t411,160.00 \t\t\t\t\t461,160.00 \t与收益相关<hr style='margin:2px; border:none;' />","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=BsP5UFYbQaeLuYQZDY4NDuMsJTW8C4Ezi6IyYuyOLyhNfnOS/7AprQ==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51386194","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"hUe6qK6K/Sg8/nD3kzHelA==","EncryptionKey":"aFVlNnFLNksvU2c4L25EM2t6SGVsQT09","Title":"以岭药业：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002603","StockTicker":"以岭药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207638458.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=YGG8BW/083+qEk5yJD3fmEM9fl+V0UI2I1nu972p4d9u0sIiUKNscg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002603/2020-04-28 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002603\t证券简称：以岭药业\t公告编号：2020-046<br />&emsp;&emsp;石家庄以岭药业股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />&emsp;&emsp;本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />非标准审计意见提示<br />"},"Highlight":{"Content":["@7@63@&emsp;&emsp;公司为国家创新型企业，先后承担和完成了两项“973”计划、“863”计划、国家自然科学基金、国家“十五”攻关、“十一五”支撑、“十二五”<em>重大新药创制</em>等三十余项国家、省部级科研项目，荣获六项国家重大科技成果大奖，何梁何利奖及一批省部级奖励，取得国内外发明专利四百余项。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51389305","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"HY2T3QBZ6o4998C1CbdLcQ==","EncryptionKey":"SFkyVDNRQlo2bzQ5OThDMUNiZExjUT09","Title":"誉衡药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002437","StockTicker":"誉衡药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207641056.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=MU4eMy57fRukEfaihmI2dmqqqM4QiNTE2/lgtkdZdkfVg/yjiA8AzA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002437/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"哈尔滨誉衡药业股份有限公司\u0000<br />证券代码：\u0000 002437 \u0000 证券简称：誉衡药业 \u0000 \u0000 公告编号：\u0000 20\u000020\u0000-\u0000034\u0000<br />&emsp;&emsp;哈尔滨誉衡药业股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51391145","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"9PwlGJsW+bmK3c10WdcN9Q==","EncryptionKey":"OVB3bEdKc1crYm1LM2MxMFdkY045UT09","Title":"科伦药业：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002422","StockTicker":"科伦药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207642719.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=eiSykpNSLNQnUb6Rl7xdzRXbJet0c+i8euXBfef+4a/iMAOuSuNA6w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002422/2020-04-28 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002422 \t证券简称：科伦药业\t公告编号：<br />&emsp;&emsp;四川科伦药业股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />董事、监事、高级管理人员异议声明<br />"},"Highlight":{"Content":["@3@46@&emsp;&emsp;在创新研发方面，科伦先后将50多亿元资金投入研发创新，拥有国家级五大创新平台，分别是：国家级企业技术中心、国家大容量注射剂工程技术研究中心、大容量注射剂国家地方联合工程实验室、注射用包装材料国家地方联合工程实验室和国家环境保护抗生素菌渣无害化处理与资源化利用工程技术中心。建立了国家级博士后科研工作站、院士工作站，迅速完成了与国际接轨的仿制药、创新药和转化医学三大功能体系的建设，成功构建以成都研究院为核心，苏州、天津、美国新泽西研究分院为分支的集约化研发体系。公司已累计获得13项“国家重点新产品”称号、先后承担12项“<em>重大新药创制</em>”科技重大项目、1项国家科技支撑计划和1项国家科技援外项目。截至2019年12月31日，科伦已申请专利3,856项，获得专利授权2,459项，在肿瘤、细菌感染、肠外营养等多个疾病领域相继启动了近500项重大药物的研制，创新专利海外授权，标志着科伦的药物研发已进入“仿制推动创新，创新驱动未来”，并成功进军国际市场的良性循环。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51391149","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"i/ta05AOeY8V0RK9oe8W6g==","EncryptionKey":"aS90YTA1QU9lWThWMFJLOW9lOFc2Zz09","Title":"科伦药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002422","StockTicker":"科伦药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207642721.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=gc2Zv9ykcwONNwgq2QdRxqaGp2TMaMxhPw/MqmdYBVr2lqejvGTWzw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002422/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;四川科伦药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />四川科伦药业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","委、国家科学技术奖励评审专家、<em>重大新药创制</em>国家科技重大专项"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51400106","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"ozFC0RsTVUHnHol0RNK3JQ==","EncryptionKey":"b3pGQzBSc1RWVUhuSG9sMFJOSzNKUT09","Title":"汉森制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002412","StockTicker":"汉森制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207644718.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=N032SrkLepivIn6sr1fy+Ox5uvklw57B98+Sde82JyxcsLrIK9HiGQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002412/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;湖南汉森制药股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;证券简称：汉森制药\u0000证券代码：\u0000 002412\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 4 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51446770","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"fK0K/qT1eznxhpi3siZQ0g==","EncryptionKey":"ZkswSy9xVDFlem54aHBpM3NpWlEwZz09","Title":"众生药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002317","StockTicker":"众生药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207643092.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=RilIRIjQWRFEJ+H74YwvN0LCt69U0IrvwnORGvc98DsX2gZS+4m4gg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002317/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;广东众生药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;广东众生\u0000药业股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","@25@205@40 \t发明专利\t一种紫杉烷类抗肿瘤药物的聚合物胶束冻干制剂及其制备方法和应用\tZL201610802372.5 \t众生药业<hr style='margin:2px; border:none;' />1\t国家“<em>重大新药创制</em>”科技重大专项课题\t2019ZX09201001-002-001\t治疗非酒精性脂肪肝炎化药一类新药WXSH0078的研究和开发\t众生睿创<hr style='margin:2px; border:none;' />","片为国家<em>重大新药创制</em>项目，也是","（国家<em>重大新药创制</em>项目）两个创新药肿瘤项目进展顺利，目前正开展","@217@2563@具有自主知识产权的抗肿瘤及其并发症新药的研发与微粒载药系统新型制剂技术平台建设\t908,750.82 \t0.00 \t0.00 \t210,999.84 \t0.00 \t0.00 \t697,750.98 \t与资产相关<hr style='margin:2px; border:none;' />“<em>重大新药创制</em>”科技重大专项2018 年度实施计划第二批立项课题\t502,410.38 \t2,218,000.00 \t0.00 \t0.00 \t0.00 \t0.00 \t2,720,410.38 \t与收益相关"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51446769","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Ec4w8sLYJMyNOV/ILuTqmw==","EncryptionKey":"RWM0dzhzTFlKTXlOT1YvSUx1VHFtdz09","Title":"众生药业：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"002317","StockTicker":"众生药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207643093.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=0E5FLD7eg35IrDpBI/An9Y6xx/9EywQBp1sx6g3jxDUrHJQLQ62jfw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002317/2020-04-28 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002317\t证券简称：众生药业\t公告编号：2020-027<br />&emsp;&emsp;广东众生药业股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />董事、监事、高级管理人员异议声明<br />"},"Highlight":{"Content":["@8@62@&emsp;&emsp;公司及子公司申请的“化药1类新药ZSP1601治疗非酒精性脂肪肝炎的I/II期临床研究”、“化药1类新药ZSP1603治疗特发性肺纤维化的I/II期临床研究”和“化学1类新药ZSP1602治疗晚期恶性肿瘤的I/II期临床研究”、“治疗非酒精性脂肪肝炎化药一类新药WXSH0078的研究和开发”、“治疗非酒精性脂肪肝炎化药一类新药WXSH0038的研究与开发”专项课题被列入国家“<em>重大新药创制</em>”科技重大专项，“治疗肝癌的一类新药ZSP1241的Ⅰ、Ⅱ期临床研究”获得广东省重点领域研发计划2018-2019年度“精准医学与干细胞”重大科技专项立项，“利巴韦林胶囊、盐酸乙胺丁醇片等12个品种仿制药一致性评价研究”、“化药1类新药ZSP1273治疗甲型流感的Ⅱ/Ⅲ期临床研究”、“核苷类药物树脂法纯化核心技术研发及产业化应用”项目获得2019年广东省重点领域研发计划重大科技专项立项。获得国家、省级重大科技专项立项是对公司创新研发项目的高度认可。专项课题项目的实施，有利于加快新药项目研发进程，强化企业技术创新主体地位，培育和聚集优秀创新创业人才团队，加强研发和科技创新转化与应用，进一步提升公司自主创新能力。","@17@121@47\t实用新型\t一种中药粉碎机\tZL201820701704.5\t益康药业<hr style='margin:2px; border:none;' />1\t国家“<em>重大新药创制</em>”科技重大专项课题\t2019ZX09201001-002-001\t治疗非酒精性脂肪肝WXSH0078的研究和开炎化药一类新药发\t众生睿创<hr style='margin:2px; border:none;' />","@17@123@&emsp;&emsp;用于治疗非酒精性脂肪性肝炎的一类创新药ZSP1601片为国家<em>重大新药创制</em>项目，也是首个完成健康人药代及安全性临床试验的用于治疗NASH的国内创新药项目，已经完成Ⅰ期临床试验并获得临床试验总结报告；ZSP1601片并且是首个进入评价NASH患者早期药效学临床试验的国内创新药项目，除获得组长单位吉林大学第一医院Ib/IIa期临床试验伦理批件，也","@18@126@&emsp;&emsp;用于治疗肝癌、胃癌等恶性肿瘤的一类创新药ZSP1241、用于治疗恶性肿瘤的一类创新药ZSP1602（国家<em>重大新药创制</em>项目）两个创新药肿瘤项目进展顺利，目前正开展Ⅰ期临床试验。注射用多西他赛聚合物胶束的已获得I期临床试验伦理批件。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51385248","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"+rigTTlnTT3HjPqhjb7mQA==","EncryptionKey":"K3JpZ1RUbG5UVDNIalBxaGpiN21RQT09","Title":"海王生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-28T00:00:00","StockCode":"000078","StockTicker":"海王生物","Url":"http://static.cninfo.com.cn/finalpage/2020-04-28/1207637636.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"零售业","ParentIndustry":"批发和零售业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=rpmyBehat5X2Yg7Jo7+2Chift/BFAX35RTycZ8qxj9GgKIEt63gmGg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000078/2020-04-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;深圳市海王生物工程股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />深圳市海王生物工程股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51358479","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"O4fTZOuvwyz8qOG9nqJZyQ==","EncryptionKey":"TzRmVFpPdXZ3eXo4cU9HOW5xSlp5UT09","Title":"上海凯宝：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-27T00:00:00","StockCode":"300039","StockTicker":"上海凯宝","Url":"http://static.cninfo.com.cn/finalpage/2020-04-27/1207612446.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=OlSVDfOQum8mzjwIedRs3NRp4gfEp91TW3oJxBJctzbhO1fBCXpvdQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300039/2020-04-27 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;上海凯宝药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />上海凯宝药业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020\u0000-\u0000021\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["@151@1732@负债项目 \t期初余额\t本期新增补助金额\t本期计入营业外收入金额\t本期计入其他收益金额\t本期冲减成本费用金额\t其他变动 \t期末余额\t与资产相关/与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>科研经费（注 3）\t332,213.29 \t\t\t142,080.00 \t\t\t190,133.29 \t与资产相关<hr style='margin:2px; border:none;' />","<em>重大新药创制</em>","@158@1827@产生其他收益的来源 \t本期发生额 \t上期发生额<hr style='margin:2px; border:none;' /><em>重大新药创制</em>科研经费 \t142,080.00 \t142,080.00<hr style='margin:2px; border:none;' />","@166@1926@种类 \t金额 \t列报项目 \t计入当期损益的金额<hr style='margin:2px; border:none;' /><em>重大新药创制</em>科研经费 \t1,320,800.00 \t递延收益 \t142,080.00<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51305926","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"+v/SHJyDWy7SLBGyHQrI9g==","EncryptionKey":"K3YvU0hKeURXeTdTTEJHeUhRckk5Zz09","Title":"天士力：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-25T00:00:00","StockCode":"600535","StockTicker":"天士力","Url":"http://static.cninfo.com.cn/finalpage/2020-04-25/1207599956.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=uAJUpsKi/zSZMZxSZpNczKEmdvdnhs4ajMMdb+cHBF4DWntIrb7TDg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600535/2020-04-25 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;2019 \u0000年年度报告\u0000<br />公司\u0000代码：\u0000 600535 \u0000 \u0000 公司简称：\u0000 天士力\u0000<br />&emsp;&emsp;天士力医药集团股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000206\u0000<br />"},"Highlight":{"Content":["规划期间获得国家<em>重大新药创制</em>科技重大专项支持的首个获批上市的","<em>重大新药创制</em>科技重大专项","（<em>重大新药创制</em>科技重","@73@972@姓名 \t主要工作经历<hr style='margin:2px; border:none;' />孙鹤\t曾任美国食品药品监督管理总局（FDA）转化医学和计量药理学首席科学家和新药评审主审官、天士力控股集团有限公司董事。现任本公司副董事长，天士力北美药业有限公司总裁、天津雅昂医药国际化发展促进有限公司总经理、创新中药关键技术国家重点实验室主任。兼任中医药世界联盟秘书长、国家教育部“2011 计划”评审专家、国家<em>重大新药创制</em>专项总体专家组委员、国家中医药标准化专家技术委员会委员，同时还兼任天津大学药学院客座教授、博导，上海交通大学医学院客座教授，台湾中国医药大学讲座教授，英国诺丁汉大学医学院特聘教授等职务。<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51305937","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"YLWgrMWBNj5JOEw/CYUI6A==","EncryptionKey":"WUxXZ3JNV0JOajVKT0V3L0NZVUk2QT09","Title":"天士力：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-25T00:00:00","StockCode":"600535","StockTicker":"天士力","Url":"http://static.cninfo.com.cn/finalpage/2020-04-25/1207599945.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=Iul50pCpNBA6+nHJnJTweNkAQfWkjJqQQW1WBlnPoEfbk/k2oeX0XA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600535/2020-04-25 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：600535 \t公司简称：天士力<br />天士力医药集团股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一、重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告..."},"Highlight":{"Content":["@3@22@&emsp;&emsp;生物药领域，构筑创新医药研发集群。天士力生物拥有已上市独家品种注射用重组人尿激酶原（普佑克）和丰富的后续在研管线，是境内稀有的研产销一体化全产业链生物药商业化平台。特异性溶栓重磅产品普佑克为中国范围内唯一获批上市的重组人尿激酶原产品，也是“十一五”规划期间获得国家<em>重大新药创制</em>科技重大专项支持的首个获批上市的Ⅰ类生物新药，自2017年7月纳入国家医保目录，迅速拉动生物药板块快速增长，成为新一代心梗特异性溶栓药物第一品牌；公司正在将普佑克的适应症从急性 ST 段抬高型心肌梗死溶栓拓展至急性缺血性脑卒中及急性肺栓塞溶栓，目前急性缺血性脑卒中适应症Ⅲ期临床试验及急性肺栓塞适应症Ⅱ期临床试验均已经全部完成病人入组工作。天士力生物还凭借在心脑血管、肿瘤及免疫、消化代谢三大治疗领域的研发优势，正在快速推进具有国际竞争优势的在研管线。公司通过自主研发和投资引进等多种方式，布局多款国际领先水平的创新药物。","@6@47@&emsp;&emsp;报告期内，公司荣获“中国医药工业百强”、“中国制药集团研发 20 强”、“2018 年度中华民族医药百强品牌企业”（中华全国工商医药业商会）、“中国工业智能制造先锋企业”(中国工业论坛组委会)、“2019中国医药创新企业100强”、“2019中国最具竞争力医药上市公司20强”（E药经理人等）、“<em>重大新药创制</em>科技重大专项-药物技术创新平台”（<em>重大新药创制</em>科技重大专项实施管理办公室）、“2019金质量奖——科技创新”（上海证券报）、“2019中国上市公司口碑榜-最佳董事会奖”（每日经济新闻）、“杰出公司治理实践上市公司”（金融界）、精准扶贫突出贡献企业（中国西部研究与发展促进会）等荣誉奖项。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51308757","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"2NEGT1rqIw4zqppzlGpIkg==","EncryptionKey":"Mk5FR1QxcnFJdzR6cXBwemxHcElrZz09","Title":"亚宝药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-25T00:00:00","StockCode":"600351","StockTicker":"亚宝药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-25/1207605658.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=9h3NGH9mDcvwY5RKtx08jGQtULsGvFdAc/H74DYc2Te3wK4hUDlfAQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600351/2020-04-25 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600351 \u0000 \u0000\t公司简称：\u0000 亚宝药业\u0000<br />&emsp;&emsp;亚宝药业集团股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000219\u0000<br />"},"Highlight":{"Content":["@149@2371@项目 \t期末余额 7,617,300.00 2,000,000.00 9,617,300.00 \t未偿还或结转的原因<hr style='margin:2px; border:none;' /><em>重大新药创制</em>科技重大专项实施管理办公室\t已经终止项目的政府补助款项，待归还<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51307042","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"++RFcBekV7RD8fa6BQXjQQ==","EncryptionKey":"KytSRmNCZWtWN1JEOGZhNkJRWGpRUT09","Title":"冠昊生物：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-25T00:00:00","StockCode":"300238","StockTicker":"冠昊生物","Url":"http://static.cninfo.com.cn/finalpage/2020-04-25/1207600902.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"专用设备制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=Kn4q+15S5QonvQSfqXzdJ1IdYUkj6JGDyTcugMInZvNtjI2sSvK2Gg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300238/2020-04-25 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：300238\t证券简称：冠昊生物\t公告编号：2020-035<br />&emsp;&emsp;冠昊生物科技股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />&emsp;&emsp;本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />&emsp;&emsp;本报告涉及的发展..."},"Highlight":{"Content":["@2@24@&emsp;&emsp;在药业领域，公司控股子公司北京文丰和中昊药业拥有1类新药苯烯莫德大中华区的自主知识产权。苯烯莫德最初发现于一种天然微生物代谢产物中分离出来的非激素类小分子化合物，是全球首个芳香烃受体激动剂（first-in-class），被国家科技部列为国家“十一五”“十二五”“十三五”“<em>重大新药创制</em>”国家科技重大专项成果。苯烯莫德产品在新药研发方面不仅在国内，在国际上也处于领先地位。","@4@51@&emsp;&emsp;2019年5月，公司成功获批上市拥有完整自主知识产权、治疗银屑病的国家1类新药本维莫德（商品名：欣比克）。本维莫德是全球首创新一代治疗炎症性和自身免疫性疾病的非激素类新型小分子化学药，是首个治疗性芳香烃受体调节剂，在同一领域具有国际领先水平，是国家科技部“十一五”、“十二五”、“十三五” “<em>重大新药创制</em>”国家科技重大专项成果。 在产业化方面，公司拥有自己的生产设施，能够满足市场对新产品上市后的产量需求。同时，公司还建立了一支专注新产品推广和销售的团队，加大了在创新药的推广和市场的投入，满足新药上市后的市场需求。","@10@115@&emsp;&emsp;报告期内，公司研发项目进展顺利，生物硬脑膜修复材料项目车间建设已完成，各项技术验证实验进行中；本维莫德关于湿疹适应症项目的临床试验进展顺利，I、II期临床试验已完成，报告期内控股子公司北京文丰承担“十三五”“<em>重大新药创制</em>”国家科技重大专项任务，进行1类新药本维莫德乳膏治疗儿童湿疹的临床研究，将扩大本维莫德乳膏的适应症，开展用于治疗湿疹的全部临床研究；截至目前，子公司北昊研究院与邓宏魁教授合作研发的生物人工肝项目取得重要进展，该项目已获得干细胞临床研究项目伦理审查批件。报告期内，公司十三五国家重点研发计划“关节软骨再生性植入材料研发及功能评价”的立项项目按照项目书内容推进；广州市科技计划项目“体外增加老龄患者软骨细胞躯体倍增次数的方法及其应用研究项目”已结题。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51307065","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"xMc+77c44AReVppyg9/xnA==","EncryptionKey":"eE1jKzc3YzQ0QVJlVnBweWc5L3huQT09","Title":"冠昊生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-25T00:00:00","StockCode":"300238","StockTicker":"冠昊生物","Url":"http://static.cninfo.com.cn/finalpage/2020-04-25/1207600907.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"专用设备制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=oXZ4fp1j1gJMFhSwNXaUy3aNNwgH0X7UMuCX2WhSiOx00cYmwN+mbA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300238/2020-04-25 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;冠昊生物科技股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />冠昊生物科技股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51310764","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"O1Wnf9i8DU6wt7tyVcnpsg==","EncryptionKey":"TzFXbmY5aThEVTZ3dDd0eVZjbnBzZz09","Title":"仙琚制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-25T00:00:00","StockCode":"002332","StockTicker":"仙琚制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-25/1207604802.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=dwDF8KkR3R/hxoMVx5dkqAMf2GHdLZRRjsO5USeWMfoayv1EiWrJLg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002332/2020-04-25 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":" \u0000 浙江仙琚制药股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />浙江仙琚制药股份有\u0000限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["@145@1779@负债项目 \t期初余额\t本期新增补助金额\t本期计入营业外收入金额\t本期计入其他收益金额\t本期冲减成本费用金额\t其他变动\t期末余额\t与资产相关/与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>专项资金补助\t4,252,771.20\t\t\t\t\t\t4,252,771.20 \t与收益相关<hr style='margin:2px; border:none;' />","@159@1959@项 目 \t期初递延收益\t本期新增补助\t本期结转 \t期末递延收益\t本期摊销列报项目\t说明<hr style='margin:2px; border:none;' /><em>重大新药创制</em>专项资金 \t4,252,771.20 \t\t\t4,252,771.20 \t其他收益 \t卫科药专项管办〔2011〕85-101-005号<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51281411","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"juOgJRPNtlfDCpcNPGTCRA==","EncryptionKey":"anVPZ0pSUE50bGZEQ3BjTlBHVENSQT09","Title":"浙江医药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-24T00:00:00","StockCode":"600216","StockTicker":"浙江医药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-24/1207585626.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=LDVRLDsvhiwHMw5yxpdB1L3ldZ+GSoGokAFmne1nFVp92QGiJZYR3Q==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600216/2020-04-24 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600216 \u0000 \u0000 公司简称：\u0000 浙江医药\u0000<br />&emsp;&emsp;浙江医药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000212\u0000<br />"},"Highlight":{"Content":["明奖。同时，公司获批一项国家“<em>重大新药创制</em>”科技重大专项项目。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51281412","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"UocFlpb/bHPnd14KAwZAQQ==","EncryptionKey":"VW9jRmxwYi9iSFBuZDE0S0F3WkFRUT09","Title":"浙江医药：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-24T00:00:00","StockCode":"600216","StockTicker":"浙江医药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-24/1207585625.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=/KGsvMkLbI+tavOdpJK3FF5baMZuDQdQNInd7KxInvdicnAukRU6yg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600216/2020-04-24 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：600216\t公司简称：浙江医药<br />浙江医药股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一 重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的..."},"Highlight":{"Content":["@8@73@&emsp;&emsp;公司项目“新型稀缺酶资源研发体系创建及其在医药领域应用”获得 2019 年度国家科技进步二等奖、教育部科技进步奖一等奖；“类胡萝卜素的合成新技术” 获2019年度浙江省科技发明奖。同时，公司获批一项国家“<em>重大新药创制</em>”科技重大专项项目。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51283538","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"aSCNp9OM9TS8YTml1Y6v7Q==","EncryptionKey":"YVNDTnA5T005VFM4WVRtbDFZNnY3UT09","Title":"振东制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-24T00:00:00","StockCode":"300158","StockTicker":"振东制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-24/1207585742.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=7Sl0ISlV0oNB88+tUGcKuHoITwE1mdUtINcdDra/weTQf/QPD33/Sw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300158/2020-04-24 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"山\u0000西\u0000振\u0000东\u0000制\u0000药\u0000股\u0000份\u0000有\u0000限\u0000公\u0000司 \u0000 2\u00000\u00001\u00009 \u0000年\u0000年\u0000度\u0000报\u0000告\u0000全\u0000文\u0000<br />山\u0000西\u0000振\u0000东\u0000制\u0000药\u0000股\u0000份\u0000有\u0000限\u0000公\u0000司\u0000<br />&emsp;&emsp;2\u00000\u00001\u00009 \u0000 年\u0000年\u0000度\u0000报\u0000告\u0000<br />&emsp;&emsp;2\u00000\u00002\u00000\u0000-\u00000\u00002\u00004\u0000<br />&emsp;&emsp;2\u00000\u00002\u00000 \u0000 年 \u0000 0\u00004 \u0000 月\u0000<br />"},"Highlight":{"Content":["@246@2602@规\"企业奖励资金<hr style='margin:2px; border:none;' /><em>重大新药创制</em>课题六味地黄片欧盟注册\t\t1,022,200.00\t \t\t\t\t1,022,200.00\t与收益相关","@247@2605@<em>重大新药创制</em>-拉洛他赛脂质微球注射液临床研究\t\t1,587,400.00\t      \t  \t\t\t1,587,400.00\t与收益相关<hr style='margin:2px; border:none;' />","@262@2820@胶铋制剂中铋含量的测定方法专利推广<hr style='margin:2px; border:none;' /><em>重大新药创制</em>课题六味地黄片欧盟注册\t1,022,200.00\t递延收益<hr style='margin:2px; border:none;' /><em>重大新药创制</em>-拉洛他赛脂质微球注射液临床研究\t1,587,400.00\t递延收益<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51224874","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"JxYEfi+Ll0nhqT7R5ig1Cw==","EncryptionKey":"SnhZRWZpK0xsMG5ocVQ3UjVpZzFDdz09","Title":"国发股份：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-21T00:00:00","StockCode":"600538","StockTicker":"国发股份","Url":"http://static.cninfo.com.cn/finalpage/2020-04-21/1207542355.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"批发业","ParentIndustry":"批发和零售业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=ZAfRsDfoV8jAhymlDKt33FOV5VsQyhE7UrZCUupdBbswzCEYdCxE/w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600538/2020-04-21 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;北海国发海洋生物产业股份有限公司 \u0000 201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600538 \u0000 \u0000 公司简称：\u0000 国发股份\u0000<br />北海国发海洋生物产业股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000163\u0000<br />"},"Highlight":{"Content":["@53@889@券有限责任公司副总裁、长城人寿保险股份有限公司副总经理。现任多闻投资基金管理（北京）有限公司董事长。2014 年 3 月起任公司独立董事。<hr style='margin:2px; border:none;' />吕秋军 \t医学博士，中国药理学会药物毒理专业委员会副主任委员、秘书长，中国毒理学会药物毒理与安全性评价专业委员会常务委员，中国药学会药物安全评价研究专业委员会委员。在国外、国内的学术期刊发表学术论文百余篇；主编《新药药理学研究方法》（2007 年 8 月化学工业出版社 出 版 ） 、 参 与 编 写 《 Drug Development - A Case Study Based Insight into Modern Strategies》等多部著作。承担“十一五”和“十二五”国家“<em>重大新药创制</em>”科技重大专项各一项，参与其他国家、军队和地方多项科研课题。1999 年军队科技进步二等奖获奖成员，2002 年北京市科技进步三等奖项目负责人。曾在西藏军区担任医生；曾在原军事医学科学院放射医学研究所药理毒理室工作，历任助理研究员、副研究员、研究员（所聘）；曾任北京杰华生物技术有限责任公司董事，杰华（北京）生物医药研究有限公司监事。现任北京杰华生物技术有限公司资深副总、杰华生物技术（青岛）有限公司副总经理。2017 年 5 月 15 日起任公司监事会主席。<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51224875","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"65glm8+z6tpRuKim+t903w==","EncryptionKey":"NjVnbG04K3o2dHBSdUtpbSt0OTAzdz09","Title":"国发股份：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-21T00:00:00","StockCode":"600538","StockTicker":"国发股份","Url":"http://static.cninfo.com.cn/finalpage/2020-04-21/1207542354.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"批发业","ParentIndustry":"批发和零售业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=CmoNJnBI/2i2GtYyD9TEEoT41xE8Tid53//qjiu+DmoPakGjtPxOJw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600538/2020-04-21 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：600538\t公司简称：国发股份<br />北海国发海洋生物产业股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一 重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 本公司董事会、监事会及董事、监事、高级管理人员保证年..."},"Highlight":{"Content":["@6@58@&emsp;&emsp;（5）国家政策对仿制药、创新药的支持，加快了新药发展，带动医药行业发展。据《中国<em>重大新药创制</em>行业市场调查研究及发展趋势预测报告（2020 年版）》显示，2016 年至 2020 年间国家重大新药专项投入和药物研发经费政府总投入均较2011年至2015年的5年间翻倍。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51225652","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"+KNhZUuemmoW6w2GafjWgA==","EncryptionKey":"K0tOaFpVdWVtbW9XNncyR2FmaldnQT09","Title":"普利制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-21T00:00:00","StockCode":"300630","StockTicker":"普利制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-21/1207539708.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=r9u4ZuErpAkcy7nTsV6eLCSqKUfGd2oJ6ejuFovyoWlVisO8OpFA1w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300630/2020-04-21 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;海南普利制药股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />海南普利制药股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020\u0000-\u0000035\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51227477","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"64vcqEGBE3tN8JuZ0f2NBQ==","EncryptionKey":"NjR2Y3FFR0JFM3ROOEp1WjBmMk5CUT09","Title":"贝达药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-21T00:00:00","StockCode":"300558","StockTicker":"贝达药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-21/1207541810.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=fgonZ+h2oNO3xlfa9KLz+5O4lxocHG+sjUHC0SzPM9qQsJDlastj1A==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300558/2020-04-21 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;贝达药业股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;目录\u0000<br />第一节 \u0000 重要提示、目录和释义 \u0000 ................................\u0000.............................\u00001..."},"Highlight":{"Content":["<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>","<em>重大新药创制</em>","@186@1832@<table class='table-highlight' border='1'><tr class='tr-highlight'><td class='td-highlight'>种类 </td><td class='td-highlight'>金额 </td><td class='td-highlight'>列报项 目</td><td class='td-highlight'>计入当期损益的金额</td></tr><tr class='tr-highlight'><td class='td-highlight'><em>重大新药创制</em>科技重大专项(卫生部财务司拨款) </td><td class='td-highlight'>760,000.00 </td><td class='td-highlight'>递延收益/其他收益 </td><td class='td-highlight'>76,000.00</td></tr><tr class='tr-highlight'><td class='td-highlight'><em>重大新药创制</em>科技重大专项（卫生部财务司拨 ）</td><td class='td-highlight'>2,900,000.00 </td><td class='td-highlight'>递延收益/其他收益 </td><td class='td-highlight'>290,000.00</td></tr><tr class='tr-highlight'><td class='td-highlight'><em>重大新药创制</em>科技重大专项-余杭区配套 </td><td class='td-highlight'>2,522,500.00 </td><td class='td-highlight'>递延收益/其他收益 </td><td class='td-highlight'>252,250.00</td></tr>","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=fgonZ+h2oNO3xlfa9KLz+5O4lxocHG+sjUHC0SzPM9qQsJDlastj1A==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51204637","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"V6jxv1tpyo3i7GQXjiyRAA==","EncryptionKey":"VjZqeHYxdHB5bzNpN0dRWGppeVJBQT09","Title":"东北制药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-20T00:00:00","StockCode":"000597","StockTicker":"东北制药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-20/1207526162.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=zLApXtPFZFgVvldF4B2zOPGvQt9a5O5C2REyDog2Bl0jSqfEJoRy4g==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000597/2020-04-20 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;东北制药集团股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />东北制药集团股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br /> \u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 0\u00004 \u0000 月\u0000<br />"},"Highlight":{"Content":["@224@2629@负债项目 \t期初余额\t本期新增补助金额\t本期计入营业外收入金额\t本期计入其他收益金额\t本期冲减成本费用金额\t其他变动 \t期末余额\t与资产相关/与收益相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>\t4,075,000.00 \t\t\t815,000.00 \t\t\t3,260,000.00 \t与资产相关<hr style='margin:2px; border:none;' />","@227@2638@制药企业溶煤回收工艺节能技术改造\t250,116.12 \t\t\t37,151.39 \t\t\t212,964.73 \t与资产相关<hr style='margin:2px; border:none;' /><em>重大新药创制</em>专项合作：磷霉素及其系列产品技术升级研究\t101,058.46 \t\t\t40,943.48 \t\t\t60,114.98 \t与资产相关<hr style='margin:2px; border:none;' />","@238@2747@产生其他收益的来源 \t本期发生额 \t上期发生额<hr style='margin:2px; border:none;' /><em>重大新药创制</em> \t815,000.00 \t815,000.00<hr style='margin:2px; border:none;' />","@239@2750@锅炉除尘节能专项资金 \t293,963.60 \t293,963.60<hr style='margin:2px; border:none;' /><em>重大新药创制</em>专项合作：磷霉素及其系列产品技术升级研究\t40,943.48 \t40,943.48<hr style='margin:2px; border:none;' />","@252@2892@种类 \t金额 \t列报项目 \t计入当期损益的金额<hr style='margin:2px; border:none;' /><em>重大新药创制</em> \t3,260,000.00 \t递延收益 \t815,000.00","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=zLApXtPFZFgVvldF4B2zOPGvQt9a5O5C2REyDog2Bl0jSqfEJoRy4g==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-86425","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Nu7SvLoDeHS/+e89wxSHZg==","EncryptionKey":"TnU3U3ZMb0RlSFMvK2U4OXd4U0haZz09","Title":"美迪西：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-16T00:00:00","StockCode":"688202","StockTicker":"美迪西","Url":"http://static.cninfo.com.cn/finalpage/2020-04-16/1207508183.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"研究和试验发展","ParentIndustry":"科学研究和技术服务业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=SwE4SyRxTPjBreOXSY3gK6janXupY43Wzfvq1feqbn707dn0w9mqQA==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688202/2020-04-16 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688202\t公司简称：美迪西<br />上海美迪西生物医药股份有限公司<br />&emsp;&emsp;2019 年年度报告<br />&emsp;&emsp;重要提示<br />一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，<br />"},"Highlight":{"Content":["@82@979@年12月在四川抗菌素工业研究所任所长兼任国药集团川抗制药有限公司董事长；2010年12月至2015年7月在中国医药工业研究总院任副院长；2013年10月至2015年9月在上海瀛科隆医药开发有限公司任董事长；2013年12月至2015年9月在国家（上海）新药安全评价中心任常务理事长；2015年至今在上海浦东科技投资有限公司任管理合伙人、副总裁。现任公司独立董事。<hr style='margin:2px; border:none;' />彭双清\t曾任国家北京药物安全评价研究中心主任、解放军疾控所毒理学评价研究中心主任、国家食品药品监督管理局新药审评专家、医疗器械审评专家、环保部新化学品审评专家、中国毒理学会副理事长，中国环境诱变剂学会常务理事。承担国家GLP技术平台建设，主持与承担国家科研课题数十项,包括973课题、863计划项目及国家“<em>重大新药创制</em>”科技专项等。现任公司临床前研究部负责人。<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51137553","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"17qFc9u2eregHofLOvCoRw==","EncryptionKey":"MTdxRmM5dTJlcmVnSG9mTE92Q29Sdz09","Title":"ST中基：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-16T00:00:00","StockCode":"000972","StockTicker":"ST中基","Url":"http://static.cninfo.com.cn/finalpage/2020-04-16/1207507407.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"农副食品加工业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=lfw2JM+taXu8P3Vad3Ev2PpNoIVKyQhJO477Pvsn4o0zF2lncfctRQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000972/2020-04-16 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;中基健康产业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;中基健康产业股份有限公司\u0000<br />CHALKIS HEALTH INDUSTRY CO.,LTD\u0000<br />&emsp;&emsp;二〇一九年年度报告全文\u0000<br />&emsp;&emsp;二〇二〇年四月\u0000<br />"},"Highlight":{"Content":["加强中医药科学研究。运用现代科学技术和传统中医药研究方法，推动<em>重大新药创制</em>。鼓励基于经典名方、医疗机构"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51120691","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"avVoFJVPW3C/8MXZI0GjNw==","EncryptionKey":"YXZWb0ZKVlBXM0MvOE1YWkkwR2pOdz09","Title":"华邦健康：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-15T00:00:00","StockCode":"002004","StockTicker":"华邦健康","Url":"http://static.cninfo.com.cn/finalpage/2020-04-15/1207499711.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"化学原料及化学制品制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=4jVAeyajl/ld5HPJindXjG2YmkKdE6NEmtLf0tNzkO+uvm0jNpzDhQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002004/2020-04-15 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;华邦生命健康股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;华邦生命健康股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["国家<em>重大新药创制</em>","@199@2423@负债项目 \t期初余额\t本期新增补助金额\t本期计入营业外收入金额\t本期计入其他收益金额\t本期冲减成本费用金额\t其他变动 \t期末余额\t与资产相关/与收益相关<hr style='margin:2px; border:none;' />\"<em>重大新药创制</em>\"（\"十二五\"第三批课题）\t3,380,000.00 \t\t\t\t\t\t3,380,000.00 \t与收益相关<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51091749","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"tpar08+CP/fe391qMWQ+9w==","EncryptionKey":"dHBhcjA4K0NQL2ZlMzkxcU1XUSs5dz09","Title":"昭衍新药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-13T00:00:00","StockCode":"603127","StockTicker":"昭衍新药","Url":"http://static.cninfo.com.cn/finalpage/2020-04-13/1207488162.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"研究和试验发展","ParentIndustry":"科学研究和技术服务业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=9x04gDLFxudi732jKajmyZagEVKwxornOZyuBMC1xMYumv3PYHyZiw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/603127/2020-04-13 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 603127 \u0000 \u0000 公司简称：\u0000 昭衍新药\u0000<br />北京昭衍新药研究中心股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000207\u0000<br />"},"Highlight":{"Content":["@22@288@丰富 \t药的临床前研究项目；公司在承担新药临床前评价项目数量和承担生物类新药临床前评价项目数量上均处于国内领先地位；<hr style='margin:2px; border:none;' />创新药评价经验丰富 \t 公司已开展超过 100 余个<em>重大新药创制</em>及其他国家计划支持的创新药物项目； 开展了数以百计的新技术药物的评价，其中抗体药物超 200 个，对于细胞治疗产品（包括 CAR-T）、基因治疗产品、溶瘤病毒以及 ADC 类产品等复杂药物的评价也积累了丰富的经验，建立了系统的评价技术。<hr style='margin:2px; border:none;' />","@70@963@姓名 \t主要工作经历<hr style='margin:2px; border:none;' />左从林 \t男，1964 年生，中国国籍，无境外永久居留权，研究生学历，研究员。1989 年毕业于中国人民解放军军事医学科学院毒物药物研究所病理学专业，获硕士学位。1989 年 7 月至 1996 年 11 月在空军航空医学研究所任助理研究员；1996 年 12 月加入本公司，历任专题负责人、药物安全性评价中心机构负责人、昭衍有限总经理，北京昭衍新药安全性评价中心机构负责人等职；从事药物安全性评价超过 20 年，作为专题负责人负责了 100 余项专题研究，作为机构负责人，组织了 300 多个新药的 1000 多项专题研究；作为专题组长，主持和参与国家“十二五”<em>重大新药创制</em>科技专项“国际化创新药物安全性评价技术平台建设”项目，作为项目负责人，组织实施了多项省市级科技项目，参与了数十项国家<em>重大新药创制</em>、国家 863 计划项目；在《毒理学杂志》等多个行业杂志和学术会议上发表论文 10 余篇；现任中国毒理学会理事、中国药理学会药物毒理专业委员会委员，本公司副董事长，全面负责公司的经营管理工作。<hr style='margin:2px; border:none;' />","@160@2368@负债项目 \t期初余额\t本期新增补助金额\t本期计入营业外收入金额\t本期计入其他收益金额\t其他变动\t期末余额\t与资产相关/与收益相关<hr style='margin:2px; border:none;' />中医药大学<em>重大新药创制</em>\t180,000.00\t466,000.00\t\t3,830.22 \t\t642,169.78\t与收益相关<hr style='margin:2px; border:none;' />","@179@2648@种类 \t金额 \t列报项目 \t计入当期损益的金额<hr style='margin:2px; border:none;' />中医药大学<em>重大新药创制</em> \t646,000.00 \t递延收益 \t3,830.22<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51068393","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Qq6g2c3SF61wOMz2UTiWsA==","EncryptionKey":"UXE2ZzJjM1NGNjF3T016MlVUaVdzQT09","Title":"健康元：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-11T00:00:00","StockCode":"600380","StockTicker":"健康元","Url":"http://static.cninfo.com.cn/finalpage/2020-04-11/1207482742.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=KJAH35Dued1JBA8RIfwKJw3CaYwnDA00UbGNhmOpzMtmCyI6MnWBsA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600380/2020-04-11 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"健康元药业集团 \u0000 \u0000\t2019 \u0000年年度报告\u0000<br />公司代码：\u0000 600380 \u0000  \u0000 公司简称：\u0000 健康元\u0000<br />&emsp;&emsp;健康元药业集团股份有限公司\u0000<br />&emsp;&emsp;600380\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />"},"Highlight":{"Content":["@216@3371@<table class='table-highlight' border='1'><tr class='tr-highlight'><td class='td-highlight'>补助项目 </td><td class='td-highlight'>种类 </td><td class='td-highlight'>上年计入损益的金额 </td><td class='td-highlight'>本年计入损益的金额 </td><td class='td-highlight'>计入损益的列报项目</td><td class='td-highlight'>与资产相关/与收益相关</td></tr><tr class='tr-highlight'><td class='td-highlight'>长效微球<em>重大新药创制</em>政府补助 </td><td class='td-highlight'>财政拨款 </td><td class='td-highlight'>4,565,450.00 </td><td class='td-highlight'>1,513,600.00 </td><td class='td-highlight'>其他收益 </td><td class='td-highlight'>与收益相关</td></tr><tr class='tr-highlight'><td class='td-highlight'>长效微球<em>重大新药创制</em>政府补助 </td><td class='td-highlight'>财政拨款 </td><td class='td-highlight'>0 </td><td class='td-highlight'>752,500.00 </td><td class='td-highlight'>其他收益 </td><td class='td-highlight'>与资产相关</td></tr>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51051675","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"XctG6U5ikWCrVwWXUA4ENg==","EncryptionKey":"WGN0RzZVNWlrV0NyVndXWFVBNEVOZz09","Title":"康缘药业：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-10T00:00:00","StockCode":"600557","StockTicker":"康缘药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-10/1207472019.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=1XAo6XSjk+wUQ9xPE9IWeJT6K9RYuifxy2BOps51jMVFv5uWG0DT/w==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600557/2020-04-10 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：600557\t公司简称：康缘药业<br />江苏康缘药业股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一 重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内..."},"Highlight":{"Content":["@5@41@&emsp;&emsp;3、公司一直高度重视已上市品种再研发，加大研发投入，并依托企业中药制药过程新技术国家重点实验室、中成药智能制造国家地方联合工程研究中心、<em>重大新药创制</em>企业大平台、国家认定企业技术中心、国家博士后科研工作站等国内领先的创新平台和技术优势，为公司产品学术推广提供有力支持，助力公司创新产品销量稳步提升。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51051676","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"GIdphdtjRZi5uVRbmuCJug==","EncryptionKey":"R0lkcGhkdGpSWmk1dVZSYm11Q0p1Zz09","Title":"康缘药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-10T00:00:00","StockCode":"600557","StockTicker":"康缘药业","Url":"http://static.cninfo.com.cn/finalpage/2020-04-10/1207472018.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=gGBfB8tsLiE0SSTrOjFPpsn40o91S4cJo+//Mn3ukGgR26xfZojxaw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600557/2020-04-10 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"江苏康缘药业股份有限公司（股票代码：\u0000 600557\u0000） \u0000  \u0000 201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600557 \u0000 \u0000\t公司简称：\u0000 康缘药业 \u0000<br />&emsp;&emsp;江苏康缘药业股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;20\u000020 \u0000 年 \u0000 4 \u0000 月\u0000<br />"},"Highlight":{"Content":["国家重点实验室、中成药智能制造国家地方联合工程研究中心、<em>重大新药创制</em>企业大平台、国家"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51040107","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"SUd60Jow4++eBE1zljKnSg==","EncryptionKey":"U1VkNjBKb3c0KytlQkUxemxqS25TZz09","Title":"凯莱英：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-09T00:00:00","StockCode":"002821","StockTicker":"凯莱英","Url":"http://static.cninfo.com.cn/finalpage/2020-04-09/1207468587.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=AmGYK6LR5HIX78CSX/51a9HZNxkLBIwBRZCtBzKhzW+q3RE/Wa6/Ug==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002821/2020-04-09 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;凯莱英医药集团（天津）股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;凯莱英医药集团（天津）股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51040100","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"xTkzkH4rsemDWxFIsn+/ww==","EncryptionKey":"eFRremtINHJzZW1EV3hGSXNuKy93dz09","Title":"凯莱英：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-09T00:00:00","StockCode":"002821","StockTicker":"凯莱英","Url":"http://static.cninfo.com.cn/finalpage/2020-04-09/1207468586.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=JdFCAQ9vQILqTh3MLKRfHMT3Hbep9szefeVY6eMWENya+X4aXVtZjg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002821/2020-04-09 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：002821 \t证券简称：凯莱英\t公告编号：2020-021凯莱英医药集团（天津）股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />董事、监事、高级管理人员异议声明<br />无<br />"},"Highlight":{"Content":["@8@87@其中，公司在日趋蓬勃发展的国内CDMO市场进展迅速。承接的国内创新药IND项目约占2019年1类化药IND申请的1/5，国内收入2019年达到2.19元，同比增长25.47%；公司服务多年的再鼎医药的则乐®（尼拉帕利）项目，于2019年11月顺利通过国家药监局核查中心关于药品注册生产现场核查及GMP检查。则乐®（尼拉帕利）是国家“十三五”“<em>重大新药创制</em>”专项，是国内首个1类新药PARP抑制剂。公司在该项目上建立了良好的示范效应，多个客户提出由公司承接NDA项目需求，目前在手订单项目超过10个。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"51028056","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"ZW3weEZWuN5vU4ffmyUetg==","EncryptionKey":"Wlczd2VFWld1TjV2VTRmZm15VWV0Zz09","Title":"安科生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-04-08T00:00:00","StockCode":"300009","StockTicker":"安科生物","Url":"http://static.cninfo.com.cn/finalpage/2020-04-08/1207462725.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=0rHXgwnOjvqSu5bbgB476uJKse3Bkbj5txPqyySNRrR7kKSRXmu2PA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300009/2020-04-08 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;安徽安科生物工程\u0000(\u0000集团\u0000)\u0000股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />安徽安科生物工程\u0000(\u0000集团\u0000)\u0000股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;公告编号：\u0000 2020\u0000-\u0000015\u0000<br />2020 \u0000 年 \u0000 04 \u0000 月\u0000<br />"},"Highlight":{"Content":["@197@2467@重组人HER2 单克隆抗体项目补助\t4,000,000.00 \t\t\t\t\t\t4,000,000.00<hr style='margin:2px; border:none;' /><em>重大新药创制</em>补助\t4,949,880.00 \t259,720.00 \t\t\t\t1,720,000.00 \t3,489,600.00 \t与收益相关<hr style='margin:2px; border:none;' />","）<em>重大新药创制</em>补助项目其他减少金额是鑫华坤公司本期将计入递延收到的该项目政府补助按照约定支付给联合申"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50920895","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"1yGPeYOqyaBU+KsVzC1lSg==","EncryptionKey":"MXlHUGVZT3F5YUJVK0tzVnpDMWxTZz09","Title":"复星医药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-31T00:00:00","StockCode":"600196","StockTicker":"复星医药","Url":"http://static.cninfo.com.cn/finalpage/2020-03-31/1207432074.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=Th082+DZm8+aArouujyHAQHhe3ssnrN2Ujx0T6frgyQu31It6RjFWw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600196/2020-03-31 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600196 \u0000 \u0000\t公\u0000司简称：\u0000 复星医药\u0000<br />&emsp;&emsp;上海复星医药（集团）股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1／361\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>科技重大专项","@56@579@序号 \t项目 \t性质 \t项目补助金额 \t报告期到账金额<hr style='margin:2px; border:none;' />1\t2019 年度<em>重大新药创制</em>国家科技重大专项——个性化抗体药物及其分子诊断试剂研发\t政府补助 \t2,290 \t0<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50920911","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"XOFM6peb2XoAhsJ7h3DIIA==","EncryptionKey":"WE9GTTZwZWIyWG9BaHNKN2gzRElJQT09","Title":"复星医药：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-31T00:00:00","StockCode":"600196","StockTicker":"复星医药","Url":"http://static.cninfo.com.cn/finalpage/2020-03-31/1207432085.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=SK4EWYKVPgK9vmf80DcBtNgMxAKQZUCZbp+EQFOlwC+GnOV8Dxp+bA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600196/2020-03-31 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：600196\t公司简称：复星医药<br />&emsp;&emsp;上海复星医药（集团）股份有限公司<br />2019年年度报告摘要\t\r\n一\t重要提示\t\t\t\r\n1\t本年度报告摘要来自\t2019\t年年度报告全文（以下简称“年度报告全文”），为全面了解本集<br />团的经营成果、财务状况及未来发展规划，投资者应当到上证所网站（http://sse.com.cn）等中国证监会指定媒体上仔细..."},"Highlight":{"Content":["@9@89@&emsp;&emsp;创新研发是医药产业发展动力，政策支持鼓励和保障是关键。在药物研发方面，国务院和相关部委先后发布了《罕见病诊疗指南（2019 年版）》、《第一批鼓励仿制药品目录》、《第三批鼓励研发申报儿童药品清单》、《第二批临床急需境外新药名单》，为药品创新研发指出品种方向。国家在创新支持方面围绕“科技重大专项”也提前开展布局，国家卫健委科教司先后印发《关于组织<em>重大新药创制</em>科技重大专项2020年度课题申报的通知》、《卫生健康“十四五”规划前期研究重大课题征集公告》、《科技重大专项相关工作规则及管理办法的通知》等政策文件，进一步优化完善政府支持鼓励医药创新的机制和举措。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-57414","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"ZBnil7QwHr41wNr9ZrWC9A==","EncryptionKey":"WkJuaWw3UXdIcjQxd05yOVpyV0M5QT09","Title":"特宝生物：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-30T00:00:00","StockCode":"688278","StockTicker":"特宝生物","Url":"http://static.cninfo.com.cn/finalpage/2020-03-30/1207423475.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=kr08+4ki7wUxgwbTEFD7L9zl3z5GTxThHccJ3jBqo5Y+6tNxYyXsrw==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688278/2020-03-30 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688278\t公司简称：特宝生物<br />厦门特宝生物工程股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />&emsp;&emsp;一 重要提示<br />1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到上海证券交易所网站等中国证监会指定媒体上仔细阅读年度报告全文。2 重大风险提示<br />"},"Highlight":{"Content":["@6@63@&emsp;&emsp;公司是中国聚乙二醇蛋白质长效药物领域的领军企业，拥有一支治疗性重组蛋白质及其长效修饰创新药物研发创新团队，入选国家科技部“重点领域创新团队”（第2013RA4020号）。“十一五”以来，该团队共计承担了9项“<em>重大新药创制</em>”国家科技重大专项，已有5个聚乙二醇蛋白质长效药物获准开展临床研究，其中1个药物获准上市。","@6@65@&emsp;&emsp;2016 年，公司历时 14 年开发的生物制品国家 1 类新药——长效干扰素派格宾获批上市，成为国内自主研发的全球首个40kD 聚乙二醇长效干扰素α -2b注射液。派格宾的药物研发及相关临床应用得到了4项“<em>重大新药创制</em>”国家科技重大专项的支持，拥有独创的结构设计及完整的专利保护，入选中国医药生物技术协会评选的当年度“中国医药生物技术十大进展”。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"kcb-57413","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"ZBnil7QwHr6e7fEQuhWqAg==","EncryptionKey":"WkJuaWw3UXdIcjZlN2ZFUXVoV3FBZz09","Title":"特宝生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-30T00:00:00","StockCode":"688278","StockTicker":"特宝生物","Url":"http://static.cninfo.com.cn/finalpage/2020-03-30/1207423476.PDF","MarketType":5,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=kr08+4ki7wUoid5fk5I2ooUg6NKr4fVjUkRrsvuQrbR584SyXRkZhw==&sector=1","ShareHref":null,"SourcePath":"kcb-filings/original/688278/2020-03-30 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"公司代码：688278\t公司简称：特宝生物<br />厦门特宝生物工程股份有限公司<br />&emsp;&emsp;2019 年年度报告<br />&emsp;&emsp;重要提示<br />一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，<br />"},"Highlight":{"Content":["@12@104@&emsp;&emsp;派格宾（通用名：聚乙二醇干扰素α -2b 注射液）是全球首个40kD 聚乙二醇干扰素 α-2b 注射液，系治疗用生物制品国家1类新药。该药品拥有完全自主知识产权，获得中、欧、美、日等多国专利授权，药物研发及相关临床应用获国家“十一五”、“十二五”、“十三五”共计4项“<em>重大新药创制</em>”国家科技重大专项持续支持。","@14@133@&emsp;&emsp;公司是中国聚乙二醇蛋白质长效药物领域的领军企业，拥有一支治疗性重组蛋白质及其长效修饰创新药物研发创新团队，入选国家科技部“重点领域创新团队”（第2013RA4020号）。“十一五”以来，该团队共计承担了9项“<em>重大新药创制</em>”国家科技重大专项，已有5个聚乙二醇蛋白质长效药物获准开展临床研究，其中1个药物获准上市。","@14@135@&emsp;&emsp;2016 年，公司历时 14 年开发的生物制品国家 1 类新药——长效干扰素派格宾获批上市，成为国内自主研发的全球首个40kD 聚乙二醇长效干扰素α-2b注射液。派格宾的药物研发及相关临床应用得到了4项“<em>重大新药创制</em>”国家科技重大专项的支持，拥有独创的结构设计及完整的专利保护，入选中国医药生物技术协会评选的当年度“中国医药生物技术十大进展”。","@16@151@&emsp;&emsp;报告期内，公司获<em>重大新药创制</em>科技重大专项实施管理办公室评为<em>重大新药创制</em>科技重大专项第一批优秀课题承担单位（国卫科药专项管办[2019]37 号，20190917）；聚乙二醇干扰素联合核苷（酸）类似物治疗慢性乙型肝炎临床治愈研究获得厦门市重大科技项目资助（课题编号：3502Z20191002）。","@19@177@&emsp;&emsp;公司凭借优良的产品质量和良好的市场服务赢得了市场的认可，并依托品牌建设、品牌传播、品牌风险防范等较完善的品牌管理体系，树立了企业和产品良好的品牌形象。公司产品“派格宾”获十一五、十二五、十三五共4项“<em>重大新药创制</em>”国家科技重大专项的支持，入选中国医药生物技术协会评选的当年度“中国医药生物技术十大进展”；“特尔津”、“特尔立”、“特尔康”被国家科学技术部评为国家火炬计划项目；特尔立还被国家科学技术部评为重点国家火炬计划项目；特尔津荣获中国科技部“产业化出口示范项目”；四个产品还获第十七届高交会优秀产品奖。企业被认定为国家创新型企业、国家高新技术企业、国家知识产权优势企业、全国企事业知识产权试点企业、福建省战略新兴产业骨干企业、福建省科技小巨人领军企业。2019年被重大新药创","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=kr08+4ki7wUoid5fk5I2ooUg6NKr4fVjUkRrsvuQrbR584SyXRkZhw==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50868808","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"qFSodVqXYMBGg045ev08WQ==","EncryptionKey":"cUZTb2RWcVhZTUJHZzA0NWV2MDhXUT09","Title":"我武生物：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-28T00:00:00","StockCode":"300357","StockTicker":"我武生物","Url":"http://static.cninfo.com.cn/finalpage/2020-03-28/1207417010.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=i8FO9ipXC1BwdONB/RnV/p+xmEwrn9aLTESR7r8BoA+/OAR04Ldajg==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300357/2020-03-28 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：300357 \t证券简称：我武生物\t公告编号：2020-019<br />&emsp;&emsp;浙江我武生物科技股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />董事、监事、高级管理人员无异议声明<br />"},"Highlight":{"Content":["@4@53@&emsp;&emsp;报告期内，公司董事会按照年度经营计划，持续重视研发创新，继续提升药品的综合研发能力，不断完善公司产品在过敏性疾病领域的覆盖能力，部分项目取得了阶段性进展：公司课题“黄花蒿粉滴剂III期临床及增加儿科适应症的临床研究”获得了<em>重大新药创制</em>科技重大专项 2019 年度实施计划立项（课题编号：2019ZX09301003）；该项目药物“黄花蒿花粉变应原舌下滴剂”用于治疗变应性鼻炎的Ⅲ期临床试验已经完成，并提出了药品注册申请（受理号：CXSS1900020国）；“黄花蒿花粉变应原舌下滴剂”对儿童变应性鼻炎患者的Ⅰ期临床试验已经完成，目前处于Ⅲ期临床试验阶段。“黄花蒿花粉点刺液”、“悬铃木花粉点刺液”、“狗毛皮屑点刺液”、“白桦花粉点刺液”、“猫毛皮屑点刺液”、“葎草花粉点刺液”、“德国小蠊点刺液”、“豚草花粉点刺液”等9项在研点刺产品的Ⅰ期临床试验已经完成；“屋尘螨皮肤点刺诊断试剂盒”于2019年3月获得了国家药品监督管理局核准签发的《药品注册批件》（国药准字S20190022）和《新药证书》（国药证书S20190001），并于2019年7月收到《药品GMP证书》（证书编号：ZJ20190085）。公司逐步形成了过敏性疾病诊疗领域多种产品协同发展的产品格局。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50868791","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"oCdNMtCsztQa1KKJj4LBEw==","EncryptionKey":"b0NkTk10Q3N6dFFhMUtLSmo0TEJFdz09","Title":"我武生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-28T00:00:00","StockCode":"300357","StockTicker":"我武生物","Url":"http://static.cninfo.com.cn/finalpage/2020-03-28/1207417028.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=I9mw0fuf2fXw2FZVdbIUXb8OwmRYeq4as0lRnHzB+3Lmo86VPJrXfA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300357/2020-03-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;浙江我武生物科技股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />浙江我武生物科技股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020-020 \u0000<br />2020 \u0000 年 \u0000 03 \u0000 月\u0000<br />"},"Highlight":{"Content":["@12@121@&emsp;&emsp;获得了<em>重大新药创制</em>科技重大专项","关于<em>重大新药创制</em>科技重大专项","《关于<em>重大新药创制</em>科技重大专项"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50869273","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"rJNKGOTyodRuAF09vw7jgA==","EncryptionKey":"ckpOS0dPVHlvZFJ1QUYwOXZ3N2pnQT09","Title":"恩华药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-28T00:00:00","StockCode":"002262","StockTicker":"恩华药业","Url":"http://static.cninfo.com.cn/finalpage/2020-03-28/1207417378.PDF","MarketType":3,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=2OVomqvA1Ric9QbadR/2SJX/w1IO30Ob3LoVAzRHmV8eKF6cfNGp7Q==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/002262/2020-03-28 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;江苏恩华药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />江苏恩华药业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 03 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","@166@1931@2018 年推动科技创新专项资金\t750,000.00 \t250,000.00 \t\t\t\t\t1,000,000.00 \t与资产相关<hr style='margin:2px; border:none;' />“<em>重大新药创制</em>”科技重大专项资金，XPO80319-3 作为非阿片类抗神经痛新药的临床研究\t911,575.00 \t\t\t\t\t\t911,575.00 \t与收益相关<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50841949","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"zHfD7+ZM+S72LG5KSgFEBg==","EncryptionKey":"ekhmRDcrWk0rUzcyTEc1S1NnRkVCZz09","Title":"广生堂：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-26T00:00:00","StockCode":"300436","StockTicker":"广生堂","Url":"http://static.cninfo.com.cn/finalpage/2020-03-26/1207405117.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=AZKcUP5o17xkJonUiud+mDGmjqtLu4De4ruU7venUwLUQnGnz0Bc1Q==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300436/2020-03-26 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;福建广生堂药业股份有限公司 \u0000 2019 \u0000年年度报告\u0000<br />福建广生堂药业股份有限公司\u0000<br />2019 \u0000 年年度报告\u0000<br />2020 \u0000 年 \u0000 03 \u0000 月\u0000<br />&emsp;&emsp;福建广生堂药业股份有限公司 \u0000 2019 \u0000年年度报告\u0000<br />"},"Highlight":{"Content":["年国家<em>重大新药创制</em>科技重大专项。","<em>重大新药创制</em>科技重大专项，","月，公司成功入选国家<em>重大新药创制</em>科技重大专项第一批优秀课题承担单位。详见公司公告："],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50841950","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"FENgHLLqQUdwHeUERYIVrA==","EncryptionKey":"RkVOZ0hMTHFRVWR3SGVVRVJZSVZyQT09","Title":"广生堂：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-26T00:00:00","StockCode":"300436","StockTicker":"广生堂","Url":"http://static.cninfo.com.cn/finalpage/2020-03-26/1207405116.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=8LpwvUcecA+fpj4pRyZqMKLQOtycbyZYaXBuqEJwAGa0ACf6rGf4iA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300436/2020-03-26 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：300436\t证券简称：广生堂\t公告编号：2020017<br />&emsp;&emsp;福建广生堂药业股份有限公司 2019 年年度报告摘要<br />一、重要提示<br />本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />大华会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：..."},"Highlight":{"Content":["@4@48@&emsp;&emsp;报告期内，GST-HG151项目已取得临床试验通知书，并被列入2019年国家<em>重大新药创制</em>科技重大专项。GST-HG151的核心化合物已申请PCT国际专利，已申请进入中国、美国、日本、欧洲、澳大利亚、加拿大等19个国家和地区。目前，已获得中国、日本的发明专利授权通知书。","@10@111@&emsp;&emsp;公司坚定不移地从传统仿制药企业向创新药企业转型，有效利用新药研发产业分工，不断提高研发效率，加快推动创新药研发进程。截至目前，GST-HG161临床I期剂量组爬坡进展顺利，GST-HG151已获批临床且其专项课题已被列入2019年国家<em>重大新药创制</em>科技重大专项，GST-HG141已获批临床、召开临床启动会并确定I期临床负责人，GST-HG131已获得临床试验通知书，GST-HG121已申请Pre-IND（临床注册前）会议。同时，公司加强创新药知识产权保护，五个创新药核心化合物均已取得中国专利授权，并陆续取得其他国家或地区专利授权，进一步夯实创新药研发先发优势。","@11@129@&emsp;&emsp;1、公司紧密围绕向创新药企业转型的发展战略，报告期内持续进行研发投入，创新药研发按计划推进，GST-HG161正处于临床I期剂量组爬坡阶段，GST-HG151已获批临床且其专项课题已被列入2019年国家<em>重大新药创制</em>科技重大专项，GST-HG141已获批临床、召开临床启动会并确定I期临床负责人，GST-HG131已获批临床成为中国首个获批临床的乙肝表面抗原（HBsAg）抑制剂，GST-HG121已申请Pre-IND（临床注册前）会议。同时，公司加强创新药知识产权保护，五个创新药核心化合物均已取得中国专利授权，并陆续取得其他国家或地区专利授权。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50841157","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"bLhJEToxVX5Qchum6O1XDg==","EncryptionKey":"YkxoSkVUb3hWWDVRY2h1bTZPMVhEZz09","Title":"丽珠集团：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-26T00:00:00","StockCode":"000513","StockTicker":"丽珠集团","Url":"http://static.cninfo.com.cn/finalpage/2020-03-26/1207404344.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=LaV5BBQSZjBF3oc0valZhCstuPhxA4n7V9/htfd8KmqpnOJanzu9SQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000513/2020-03-26 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"丽珠医药集团股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年\u0000年度报告\u0000<br />2020 \u0000 年 \u0000 3 \u0000 月\u0000<br />&emsp;&emsp;目录\u0000<br />董事长致辞 \u0000 ................................\u0000 ............... \u0000 1\u0000财务摘要 \u0000 ................................\u0000 ....."},"Highlight":{"Content":["长效微球<em>重大新药创制</em>政府补助","长效微球<em>重大新药创制</em>政府补助"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50801959","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"eGvP/Rp6s4+Y3xzwYcQgnQ==","EncryptionKey":"ZUd2UC9ScDZzNCtZM3h6d1ljUWduUT09","Title":"恒瑞医药：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-23T00:00:00","StockCode":"600276","StockTicker":"恒瑞医药","Url":"http://static.cninfo.com.cn/finalpage/2020-03-23/1207391538.PDF","MarketType":1,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=/MMT0H0xy5lkNj6sIPr2Wi8//1SyBzb/QM7uoWYIz3blLm9r3u5N4Q==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/600276/2020-03-23 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;201\u00009 \u0000年年度报告\u0000<br />公司代码：\u0000 600276 \u0000 \u0000 公司简称：\u0000 恒瑞医药\u0000<br />江苏恒瑞医药股份有限公司 \u0000<br />&emsp;&emsp;2019 \u0000 年年度报告 \u0000<br />&emsp;&emsp;1 \u0000/ \u0000146\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","国家<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50786927","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"1tUhU5T1L8uEaL7Epy5c6w==","EncryptionKey":"MXRVaFU1VDFMOHVFYUw3RXB5NWM2dz09","Title":"沃森生物：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-21T00:00:00","StockCode":"300142","StockTicker":"沃森生物","Url":"http://static.cninfo.com.cn/finalpage/2020-03-21/1207390982.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=xXwgKe0VguzoloPZ2ov4KBH2KqUu/QlRYg3XFTYmUZgxX0lui+W77A==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300142/2020-03-21 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp; \u0000 云南沃森生物技术股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020\u0000-\u0000016\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 03 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["<em>重大新药创制</em>","<em>重大新药创制</em>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50786928","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"Ae8HRippFQch2TtoliEr3A==","EncryptionKey":"QWU4SFJpcHBGUWNoMlR0b2xpRXIzQT09","Title":"沃森生物：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-21T00:00:00","StockCode":"300142","StockTicker":"沃森生物","Url":"http://static.cninfo.com.cn/finalpage/2020-03-21/1207390981.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=+5cskNZ6HOP95jY1Y1uPHwe3ckYUO/T3NsKGzUZKYDEnFvjk86eMuQ==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300142/2020-03-21 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：300142\t证券简称：沃森生物\t公告编号：2020-017<br />&emsp;&emsp;云南沃森生物技术股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />一、重要提示<br />&emsp;&emsp;本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒体仔细阅读年度报告全文。<br />"},"Highlight":{"Content":["@2@19@&emsp;&emsp;公司是专业从事人用疫苗等生物技术药集研发、生产、销售于一体的高科技生物制药企业，在以新型疫苗为代表的生物技术药细分领域处于行业领先地位。经过近二十年的发展，公司已形成了结构优良、品种丰富的产品管线，拥有全球两大重磅疫苗品种13价肺炎结合疫苗和HPV疫苗，并构建了国内领先的研发和产业化技术平台，聚集了一大批中西合璧的专业技术和管理人才，获得了一批国家“863计划”和“<em>重大新药创制</em>”科技重大专项支持，与盖茨基金会等国际著名机构建立了紧密的合作关系。"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50729306","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"RLIFV01hPs8eSu0Gd4q7Fg==","EncryptionKey":"UkxJRlYwMWhQczhlU3UwR2Q0cTdGZz09","Title":"舒泰神：2019年年度报告摘要","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-17T00:00:00","StockCode":"300204","StockTicker":"舒泰神","Url":"http://static.cninfo.com.cn/finalpage/2020-03-17/1207378046.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=waC1RF+wIFAidgQAiHVjWGvaeacVY4Rge/zzpwr6000Xwa//mab2NA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300204/2020-03-17 2019年年度报告摘要.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"证券代码：300204 \t证券简称：舒泰神\t公告编号：2020-12-04<br />&emsp;&emsp;舒泰神(北京)生物制药股份有限公司<br />&emsp;&emsp;2019 年年度报告摘要<br />&emsp;&emsp;一、重要提示<br />&emsp;&emsp;1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指定媒..."},"Highlight":{"Content":["@3@31@药物类型\t项目名称\t临床适应症\t目前研发进展\t核心竞争优势\t项目成果情况<hr style='margin:2px; border:none;' />蛋白药物\t单克隆抗体药物BDB-001注射液\t中重度化脓性汗腺炎\t临床I期：已有部分患者入组主要研究者：中国医学科学院北京协和医院陈锐教授\t全球创新靶点，拥有完善的专利保护体系，有望广泛应用于自身免疫性疾病和感染性疾病\t“国家<em>重大新药创制</em>”科技重大专项纳入药品注册特殊审批程序<hr style='margin:2px; border:none;' />基因治疗/细胞治疗药物\tSTSG-0002注射液\t乙型肝炎病毒感染相关疾病\t临床I期：已获得伦理委员会批件；主要研究者：北京大学第一医院王贵强主任、崔一民主任\t全球新靶点、新作用机制，自主研发的基因治疗药物，属于I类生物制品，拥有完善的知识产权布局、业界领先的生产工艺和质量控制体系，临床前研究表明具有卓越的有效性和长效性，市场空间广阔\t“国家<em>重大新药创制</em>”科技重大专项纳入药品注册特殊审批程序<hr style='margin:2px; border:none;' />治疗艾滋病的细胞治疗药物\t艾滋病毒感染相关疾病\t临床前研究\t全球新靶点、新作用机制，自主研发的细胞治疗药物，属于I类生物制品，拥有完善的知识产权布局、专业的研发技术平台，有望成为艾滋病治疗中长效作用且疗效更优的解决方案\t“国家<em>重大新药创制</em>”科技重大专项<hr style='margin:2px; border:none;' />","@4@35@&emsp;&emsp;苏肽生于1995年开始研发，2006年获得国家食品药品监督管理局颁发的新药证书和生产批文并开始上市销售。苏肽生是我国神经生长因子领域第一个国药准字号产品，是具有自主知识产权的国家一类新药，适应症为“具有促进神经损伤恢复的作用。用于治疗视神经损伤”。苏肽生的两项研发课题被列为“国家十二五<em>重大新药创制</em>项目”；获得北京市科学技术进展三等奖；苏肽生的产业化被列为国家发改委“国家高技术产业发展项目”、国家发改委和经信委联合审评的“重点产业振兴和技术改造专项项目”。为不断拓展苏肽生的临床应用领域，公司不断研发拓展新适应症并在2016年分别取得苏肽生新增“糖尿病足”和“创伤性周围神经损伤”适应症的临床批件。","@11@96@药物类型\t项目名称\t临床适应症\t目前研发进展\t核心竞争优势\t项目成果情况<hr style='margin:2px; border:none;' />蛋白药物\t单克隆抗体药物BDB-001注射液\t中重度化脓性汗腺炎\t临床I期：已有部分患者入组主要研究者：中国医学科学院北京协和医院陈锐教授\t全球创新靶点，拥有完善的专利保护体系，有望广泛应用于自身免疫性疾病和感染性疾病\t“国家<em>重大新药创制</em>”科技重大专项纳入药品注册特殊审批程序<hr style='margin:2px; border:none;' />基因治疗/细胞治疗药物\tSTSG-0002注射液\t乙型肝炎病毒感染相关疾病\t临床I期：已获得伦理委员会批件；主要研究者：北京大学第一医院王贵强主任、崔一民主任\t全球新靶点、新作用机制，自主研发的基因治疗药物，属于I类生物制品，拥有完善的知识产权布局、业界领先的生产工艺和质量控制体系，临床前研究表明具有卓越的有效性和长效性，市场空间广阔\t“国家<em>重大新药创制</em>”科技重大专项纳入药品注册特殊审批程序<hr style='margin:2px; border:none;' />治疗艾滋病的细胞治疗药物\t艾滋病毒感染相关疾病\t临床前研究\t全球新靶点、新作用机制，自主研发的细胞治疗药物，属于I类生物制品，拥有完善的知识产权布局、专业的研发技术平台，有望成为艾滋病治疗中长效作用且疗效更优的解决方案\t“国家<em>重大新药创制</em>”科技重大专项<hr style='margin:2px; border:none;' />","@13@112@&emsp;&emsp;政府支持方面，2019年03月，公司及子公司德丰瑞收到国家<em>重大新药创制</em>科技重大专项支持“人源化C5a抗体（BDB-001）研究”资金480万元。“人源化C5a抗体（BDB-001）研究”是公司在十一五、十二五和十三五期间承担的第5个“<em>重大新药创制</em>”科技重大专项，相信随着这些技术平台、创新药物的成熟发展与转化上市，能够为推动我国自主创新的生物药物的产业化与国际化做出公司的贡献。此外，2019年04月，公司收到北京市经信局高精尖产业创新集群支持“舒泰神固体制剂车间建设项目”资金600万元，为公司快速发展的舒泰清等系列产品的智能制造、绿色制造升级增加了有力的支撑。2019年09月，公司收到通知，根据《〈关于精准支持中关村国家自主创新示范区重大前沿项目与创新平台建设的若干措施〉实施办法（试行）》（中科园发〔2019〕25号），公司“单克隆抗体原创新药关键技术成果转化”项目被列"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50729304","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"K+oNKbe9NECCSprbKP4Dow==","EncryptionKey":"SytvTktiZTlORUNDU3ByYktQNERvdz09","Title":"舒泰神：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-17T00:00:00","StockCode":"300204","StockTicker":"舒泰神","Url":"http://static.cninfo.com.cn/finalpage/2020-03-17/1207378050.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=9wJnwMR84xr2okaQ1g+97SrPfmfDXqMviL6++qE3EXrQIy+aWxKMXw==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300204/2020-03-17 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;舒泰神\u0000(\u0000北京\u0000)\u0000生物制药股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />舒泰神\u0000(\u0000北京\u0000)\u0000生物制药股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 03 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["@13@117@<table class='table-highlight' border='1'><tr class='tr-highlight'><td class='td-highlight'>药物类型 </td><td class='td-highlight'>项目名称 </td><td class='td-highlight'>临床适应症 </td><td class='td-highlight'>目前研发进展 </td><td class='td-highlight'>核心竞争优势 </td><td class='td-highlight'>项目成果情况</td></tr><tr class='tr-highlight'><td class='td-highlight'>蛋白药物</td><td class='td-highlight'>单克隆抗体药物BDB-001注射液</td><td class='td-highlight'>中重度化脓性汗腺炎</td><td class='td-highlight'>临床I期：已有部分患者入组主要研究者：中国医学科学院北京协和医院陈锐教授</td><td class='td-highlight'>全球创新靶点，拥有完善的专利保护体系，有望广泛应用于自身免疫性疾病和感染性疾病</td><td class='td-highlight'>“国家<em>重大新药创制</em>”科技重大专项纳入药品注册特殊审批程序</td></tr><tr class='tr-highlight'><td class='td-highlight'>基 因 治 疗 /细胞治疗药物</td><td class='td-highlight'>STSG-0002注射液</td><td class='td-highlight'>乙型肝炎病毒感染相关疾病</td><td class='td-highlight'>临床I期：已获得伦理委员会批件；主要研究者：北京大学第一医院王贵强主任、崔一民主任</td><td class='td-highlight'>全球新靶点、新作用机制，自主研发的基因治疗药物，属于I类生物制品，拥有完善的知识产权布局、业界领先的生产工艺和质量控制体系，临床前研究表明具有</td><td class='td-highlight'>“国家<em>重大新药创制</em>”科技重大专项纳入药品注册特殊审批程序</td></tr></table>","@14@120@卓越的有效性和长效性，市场空间广阔<hr style='margin:2px; border:none;' />治疗艾滋病的细胞治疗药物\t艾滋病毒感染相关疾病\t临床前研究\t全球新靶点、新作用机制，自主研发的细胞治疗药物，属于I类生物制品，拥有完善的知识产权布局、专业的研发技术平台，有望成为艾滋病治疗中长效作用且疗效更优的解决方案\t“国家<em>重大新药创制</em>”科技重大专项<hr style='margin:2px; border:none;' />","国家十二五<em>重大新药创制</em>项目","月，公司及子公司德丰瑞收到国家<em>重大新药创制</em>科技重大专项","个“<em>重大新药创制</em>”科技重大专项，相信随","<center><a target=\"_blank\" href=\"/Home/FilingDetail?key=9wJnwMR84xr2okaQ1g+97SrPfmfDXqMviL6++qE3EXrQIy+aWxKMXw==&sector=1\"><b>更多匹配结果...</b></a></center>"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":true,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50681303","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"JMeA/f/a1k9GEFjzkqV1ag==","EncryptionKey":"Sk1lQS9mL2ExazlHRUZqemtxVjFhZz09","Title":"香雪制药：2017年年度报告（更新后）","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-12T00:00:00","StockCode":"300147","StockTicker":"香雪制药","Url":"http://static.cninfo.com.cn/finalpage/2020-03-12/1207368148.PDF","MarketType":4,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=witeJ+5tBaM3QzCL7730/LY6g2sqC4wnuaMwo8GLlPhYC+svX0ts5Q==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/300147/2020-03-12 2017年年度报告（更新后）.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"&emsp;&emsp;广州市香雪制药股份有限公司 \u0000 2017 \u0000年年度报告全文\u0000<br />广州市香雪制药股份有限公司\u0000<br />&emsp;&emsp;2017 \u0000 年年度报告\u0000<br />&emsp;&emsp;2018\u0000-\u00000\u000019\u0000<br />&emsp;&emsp;2018 \u0000 年 \u0000 03 \u0000 月\u0000<br />"},"Highlight":{"Content":["模式，实现中成药业务的健康、持续发展，探索适合中药特点的新药开发新模式，推动<em>重大新药创制</em>和中"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]},{"Id":"50667183","Sector":0,"Source":{"DocumentId":null,"DocumentKey":null,"Label":null,"Id":null,"Key":"fM5iXhkijeR9OhO6bV/amQ==","EncryptionKey":"Zk01aVhoa2lqZVI5T2hPNmJWL2FtUT09","Title":"普洛药业：2019年年度报告","Attachments":[],"Paragraphs":[],"EngParagraphs":[],"UnigramParagraphs":[],"Pages":[],"QaPairs":[],"SubTitles":[],"PublishDate":"2020-03-12T00:00:00","StockCode":"000739","StockTicker":"普洛药业","Url":"http://static.cninfo.com.cn/finalpage/2020-03-12/1207364300.PDF","MarketType":2,"NoticeType":"年度报告","Industry":"医药制造业","ParentIndustry":"制造业","Province":"","IntermediaryName":null,"IntermediaryType":0,"RelevantLaws":[],"Href":"/Home/FilingDetail?key=3WhFb7I3H84JIy1uOGmFNJe+zv4BHdKTN7UKx1WYbMqCj2f8UINJbA==&sector=1","ShareHref":null,"SourcePath":"a-filings/original/000739/2020-03-12 2019年年度报告.PDF","TotalPage":0,"FileType":1,"Availability":1,"IsDir":0,"IsFav":false,"Preview":"普洛药业股份有限公司 \u0000 2019 \u0000年年度报告全文\u0000<br />&emsp;&emsp;普洛药业股份有限公司\u0000<br />&emsp;&emsp;2019 \u0000 年年度报告\u0000<br />&emsp;&emsp;2020 \u0000 年 \u0000 03 \u0000 月\u0000<br />&emsp;&emsp;1\u0000<br />"},"Highlight":{"Content":["@158@2113@头孢注射制剂、头孢口服制剂和青霉素口服制剂项目\t1,303,333.33\t\t\t230,000.00\t\t\t1,073,333.33\t与资产相关<hr style='margin:2px; border:none;' />创新团队配套资金&<em>重大新药创制</em>\t4,090,000.00\t1,320,000.00\t\t1,331,533.02\t\t\t4,078,466.98\t与收益相关","@165@2198@头孢注射、口服制剂和青霉素口服制剂项目补助\t230,000.00 \t230,000.00<hr style='margin:2px; border:none;' /><em>重大新药创制</em>-索法地尔项目补助 \t\t2,800,000.00<hr style='margin:2px; border:none;' />"],"Title":[],"Adjacent":[],"Diff":[],"HasMore":false,"Keywords":[]},"IOSHighlight":{"Content":[],"Title":[]},"KeywordFrequencies":[]}],"GroupKey":null,"GroupHits":[],"Aggregations":[{"AggKey":"companyCount","AggName":null,"Items":[{"N":"total","C":56,"M":0,"JsonTag":null}],"ItemList":[]},{"AggKey":"company","AggName":null,"Items":[{"N":"300147 香雪制药","C":3,"M":0,"JsonTag":null},{"N":"000989 九芝堂","C":2,"M":0,"JsonTag":null},{"N":"002107 沃华医药","C":2,"M":0,"JsonTag":null},{"N":"002317 众生药业","C":2,"M":0,"JsonTag":null},{"N":"002422 科伦药业","C":2,"M":0,"JsonTag":null},{"N":"002603 以岭药业","C":2,"M":0,"JsonTag":null},{"N":"002750 龙津药业","C":2,"M":0,"JsonTag":null},{"N":"002755 奥赛康","C":2,"M":0,"JsonTag":null},{"N":"002793 罗欣药业","C":2,"M":0,"JsonTag":null},{"N":"002821 凯莱英","C":2,"M":0,"JsonTag":null},{"N":"300142 沃森生物","C":2,"M":0,"JsonTag":null},{"N":"300204 舒泰神","C":2,"M":0,"JsonTag":null},{"N":"300238 冠昊生物","C":2,"M":0,"JsonTag":null},{"N":"300357 我武生物","C":2,"M":0,"JsonTag":null},{"N":"300436 广生堂","C":2,"M":0,"JsonTag":null},{"N":"600196 复星医药","C":2,"M":0,"JsonTag":null},{"N":"600216 浙江医药","C":2,"M":0,"JsonTag":null},{"N":"600351 亚宝药业","C":2,"M":0,"JsonTag":null},{"N":"600535 天士力","C":2,"M":0,"JsonTag":null},{"N":"600538 国发股份","C":2,"M":0,"JsonTag":null},{"N":"600557 康缘药业","C":2,"M":0,"JsonTag":null},{"N":"688177 百奥泰","C":2,"M":0,"JsonTag":null},{"N":"688266 泽璟制药","C":2,"M":0,"JsonTag":null},{"N":"688278 特宝生物","C":2,"M":0,"JsonTag":null},{"N":"000078 海王生物","C":1,"M":0,"JsonTag":null},{"N":"000513 丽珠集团","C":1,"M":0,"JsonTag":null},{"N":"000566 海南海药","C":1,"M":0,"JsonTag":null},{"N":"000597 东北制药","C":1,"M":0,"JsonTag":null},{"N":"000739 普洛药业","C":1,"M":0,"JsonTag":null},{"N":"000931 中关村","C":1,"M":0,"JsonTag":null},{"N":"000972 ST中基","C":1,"M":0,"JsonTag":null},{"N":"002004 华邦健康","C":1,"M":0,"JsonTag":null},{"N":"002262 恩华药业","C":1,"M":0,"JsonTag":null},{"N":"002287 奇正藏药","C":1,"M":0,"JsonTag":null},{"N":"002332 仙琚制药","C":1,"M":0,"JsonTag":null},{"N":"002412 汉森制药","C":1,"M":0,"JsonTag":null},{"N":"002437 誉衡药业","C":1,"M":0,"JsonTag":null},{"N":"300009 安科生物","C":1,"M":0,"JsonTag":null},{"N":"300039 上海凯宝","C":1,"M":0,"JsonTag":null},{"N":"300108 吉药控股","C":1,"M":0,"JsonTag":null},{"N":"300158 振东制药","C":1,"M":0,"JsonTag":null},{"N":"300199 翰宇药业","C":1,"M":0,"JsonTag":null},{"N":"300558 贝达药业","C":1,"M":0,"JsonTag":null},{"N":"300601 康泰生物","C":1,"M":0,"JsonTag":null},{"N":"300630 普利制药","C":1,"M":0,"JsonTag":null},{"N":"600079 人福医药","C":1,"M":0,"JsonTag":null},{"N":"600129 太极集团","C":1,"M":0,"JsonTag":null},{"N":"600276 恒瑞医药","C":1,"M":0,"JsonTag":null},{"N":"600380 健康元","C":1,"M":0,"JsonTag":null},{"N":"600518 ST康美","C":1,"M":0,"JsonTag":null},{"N":"600568 *ST中珠","C":1,"M":0,"JsonTag":null},{"N":"600781 *ST辅仁","C":1,"M":0,"JsonTag":null},{"N":"603127 昭衍新药","C":1,"M":0,"JsonTag":null},{"N":"603858 步长制药","C":1,"M":0,"JsonTag":null},{"N":"603998 方盛制药","C":1,"M":0,"JsonTag":null},{"N":"688202 美迪西","C":1,"M":0,"JsonTag":null}],"ItemList":[]}],"HighlightFilters":[{"Keyword":"重大新药创制","IsApplied":false}],"TitleHighlights":[],"ContentHighlights":[],"IpoItems":[],"Message":null,"NickName":null,"PaymentStatus":"1","SubscriptionLimit":"20","CanPay":true,"ExpireTime":"2021-08-29","ResponseCode":100,"ResponseMessage":"","Token":"nmRnY1j%2bCGXKCM4bM4TTn3jQHDvW7eGIToGnu4ZfJe7o87Tw1S6SoYeBvRf7P4zvFXODclaHtVxIRE7b0lMXAdV6YpyuqxpGH84D1n0f2sR6vD%2bBGy45OvR6KoTmHezOaKkH6pr2ZE6g%2fpE%2bXsF1WQ%3d%3d","CommonSession":null}